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EXECUTIVE SUMMARY 
Arrangements between university researchers and industry have been commonplace for 
decades.1-3 The typical arrangement involves a private sponsor, such as a pharmaceutical 
company providing a grant, contract or some other form of financial support to an academic 
investigator to conduct an individual study (e.g., a clinical trial) or pursue a line of research (e.g., 
a set of studies examining different forms of treatment for heart disease) that is of interest to the 
company and also falls within the scientific expertise and interest of the investigator. While such 
relationships are, at least prima facie, intended to be mutually beneficial, they can present 
conflicts of interest and commitment for the university-based researchers.  It was because of 
these risks of conflict that rules, regulations, and guidelines for managing such conflicts were 
developed by federal regulators, professional associations and the academic community 
generally.4-9 Indeed, the level of scrutiny for such arrangements has never been greater.10  
A separate type of industry-academic arrangement is also appearing in the form of broader 
partnerships, platforms and collaborations where joint agreements are developed to pursue 
common areas of research, data analysis or drug development.11,12  These arrangements vary but 
they differ in substantive ways from the more traditional grant-supported investigator model, 
often in the length of the time horizon, the arrangement’s financial structure, its expectations of 
reciprocal benefit, and potential for impact at both organizations. The Massachusetts Institute of 
Technology was among the first to develop and implement these kinds of arrangements.13 
Indeed, even the country’s premier public biomedical research sponsor, the National Institutes of 
Health, ventured into this territory when it announced in 2012 that its National Center for 
Advancing Translational Sciences (NCATS) “has unveiled a collaborative program that will 
match researchers with a selection of pharmaceutical industry compounds to help scientists 
explore new treatments for patients”.14  
In 2012, the Regenstrief Institute entered into a new partnership with the pharmaceutical 
company Merck with the goal of improving “the health of patients through data analytics, health 
care innovation, education and research that supports evidence-based health care.”15  In March of 
2013, the Indiana University Center for Bioethics (IUCB) was asked to evaluate the Regenstrief 
component of the partnership from an ethics perspective. This was a unique opportunity since 
few such assessments have been reported in the literature. 
The Study 
The principal goal of the IUCB study was to provide substantive actionable recommendations 
to minimize the risk that potential or actual conflicts of interest might affect the scientific 
processes and outcomes of Regenstrief and its investigators. The study was also designed to 
provide an assessment of how well the partnership was meeting a standard for what an “ethically 
credible” partnership should look like. Although frameworks have been developed for assessing 
ethical acceptability in other areas of health care,16,17 the idea to apply such an approach to 
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academic-industry partnerships was new.  Therefore, the study provided an opportunity to design 
new tools that would help Regenstrief assess its current partnership and, if they proved useful, to 
aid in assessing future partnerships. The study was undertaken from October 2013 to September 
2014 and conducted by faculty and staff from the IU Center for Bioethics 
(www.bioethics.iu.edu) using an approach consisting of five components: 
(1) Regular meetings with Regenstrief leadership involved in the partnership that provided 
regular feedback to the project team, including one focus group to understand needs;  
(2) Comprehensive review of the scholarly literature to identify current empirical findings 
about successful and unsuccessful partnerships, ethical assessments, and policy analyses; 
(3) Analysis of key partnership documents including the master contract, handbooks for 
investigators and related materials; 
(4) Development of a new evaluation tool consisting of a set of 9 substantive ethical principles 
and 23 benchmarks for ethically credible academic-industry partnerships (See Table 1) and;  
(5) Conduct of an online, anonymous survey of Regenstrief investigator knowledge of and 
attitudes about the partnership to further inform the analysis.  
The group provided two deliverables:  
Deliverable #1: An annotated bibliography arising from the review of 25 publications from the 
peer reviewed literature; the ethical principles; and the benchmarks.  
Deliverable #2: A final report including analysis of survey results and proposed 
recommendations. 
Main Conclusions 
1. While it was not task of this study to declare the Merck-Regenstrief partnership as “ethical” 
or “unethical,” we concluded that Regenstrief is engaged in an “ethically credible” 
partnership.  We came to this conclusion by determining that a majority of the ethical 
principles and benchmarks developed for ethically-credible partnerships were met. 
Regenstrief is engaged in an innovative and exciting partnership which substantially met the 
evaluative criteria that were jointly developed for this purpose.  
2.  Regenstrief’s governance practices include procedures and policies that anticipate and 
address many of the key ethical issues that would be expected to arise in such partnerships.  
3. While some principles and benchmarks were not fully met or a clear assessment was not 
possible, specific recommendations were made that, if followed, could assist Regenstrief in 
meeting or exceeding the benchmarks in the future. Indeed, we are convinced that with minor 
modifications, the approach taken by Regenstrief may serve as a model for other academic-
industry partnerships. 
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Recommendations 
In general, the recommendations addressed three main areas: (1) transparency and knowledge 
about the partnership; (2) conflict of interest policy; and (3) ongoing review of the partnership 
and its perception among Regenstrief investigators. Attending to these items could commend this 
type of partnership to others who are contemplating similar arrangements.  
Recommendation #1: Increase transparency by providing more opportunities for 
investigators to become educated about the partnership, especially in areas where lack of 
understanding could potentially lead to an erosion of trust among Regenstrief investigators.  
 
We believe that this can be achieved in a number of ways: 
• In addition to the handbook that emailed to all eligible investigators, Regenstrief could 
hold an annual meeting where projects recently completed or being conducted in the 
partnership are reported to all investigators. This could spur interest in the partnership 
and also correct misinformed opinions about the partnership. 
• At the conclusion of this review, hold a “town hall” meeting where these results could be 
presented to Regenstrief investigators and leadership would be able to provide 
information where seemingly problematic issues arise and investigators could further 
elaborate on the identified areas. 
• At the conclusion of this review, write a memorandum of the findings joined with 
educational information on the partnership to be sent to all Regenstrief investigators. 
 
Recommendation #2: Increase transparency in the project selection process by establishing 
and making explicit to all investigators how projects are selected and what criteria are used. 
We believe that this could be achieved in a number of ways: 
• Providing details about the process, and include it in the investigator handbook for the 
partnership. 
• Allow an unaffiliated and unbiased observer to sit in on the project selection meetings in 
order to form an objective description of the process. This person would ideally be 
qualified to offer recommendations on improving process after seeing how the committee 
selects projects. 
 
Recommendation #3: Regenstrief should seek additional ways to engage more 
investigators in the partnership.  
We believe that this could be achieved in a number of ways: 
• Distinguishing announcements for this call for proposals from all others (e.g., NIH, 
PCORI, etc.) so as to draw attention to them in Regenstrief email. 
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• Holding an annual Regenstrief WIP on the research outcomes of the partnership and use 
the opportunity to discuss the partnership and the next call for proposals. 
 
Recommendation #4: In addition to the extant conflict of interest disclosure policies 
required by the IU School of Medicine, Regenstrief should establish and publicize widely 
partnership-specific conflict of interest (COI) policies. 
We believe this could be accomplished in a number of ways: 
• Requesting COI self-disclosure from investigators akin to the IU policy when selected 
projects are funded. 
• Requesting COI self-disclosure from investigators akin to the IU policy as a part of the 
initial proposal process. That is, an essential part of the proposal submitting process 
includes disclosing potential conflicts of interest. 
• Issue a join position paper by Regenstrief and Merck on conflicts of interests and 
circulate it to relevant bodies and personnel. 
 
Recommendation #5: Regenstrief should continue to reach out to investigators who may 
have concerns about the partnership and provide opportunities for learning, consultation and 
input. 
This could be accomplished in a number of ways: 
• Conduct a more comprehensive assessment of Regenstrief investigator knowledge and 
attitudes about this partnership and other partnerships, which includes one-on-one 
interviews or focus groups. 
• Providing an open and non-threatening opportunity for investigators to express concerns 
about the partnership.  
• Ensure that Regenstrief investigators are aware of and encouraged to make use of the 
CTSI Bioethics and Subject Advocacy Program consultation service.  
 
Methodological Considerations 
 
Given that this study was one of the first of its kind undertaken, we are aware that there are areas 
where improvement could be achieved. Since the use of principles and benchmarks has, to our 
knowledge, never been used to assess the ethical credibility of an industry-academic partnership 
before, further research may be needed to confirm the value of this approach and refinements 
made as necessary. We chose to use the results of an investigator survey as empirical indicators 
of achievement, but other methods may be equally or more appropriate. 
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PRINCIPLES        BENCHMARKS 
  
Academic Freedom 1. Promote investigator-initiated science and protect the ability to attract and maintain federal research support. 
 2. Permit investigators to initiate or continue collaboration with any other qualified group, person, or entity. 
 3. Ensure that all investigators involved in the partnership are given equal opportunity to submit proposals for funding. 
 4. Avoid obligating faculty to work outside their own self-defined scientific area. 
 
Conflict of Interest 
Policy and Management 
 
5. Protect students, fellows, and post-doctoral fellows involved in collaborative projects from exploitation. 
6. Ensure that effective mechanisms exist to eliminate, control or manage conflicts of interest in the partnership. 
  
Intellectual Property 
 
 
7. Ensure all investigators and both partners retain their proprietary and intellectual property rights throughout and after the 
partnership. 
 
Data Sharing, Access 8. Ensure that data sharing arrangements are explicit and that all rights to access data are fairly negotiated at the outset of 
the partnership. 
  
Effective Governance 9. Establish parameters for what type of projects will and will not be funded (e.g. add-on projects, training, pilot studies). 
 10. Create ways to protect each party from an unexpected end to the partnership. 
 11. Assess formally the efficiency, effectiveness, and achievements of the partnership on an annual basis. 
 12. Ensure that clear, comprehensive, and efficient procedures exist for all governance entities of the partnership and are 
known to all investigators. 
  
Protection of Human 
Subjects 
13. Ensure that all investigators, staff and other participants in the partnership have adequate training in the responsible 
conduct of research and related ethical issues. 
14. Ensure that all projects in the partnership aim to satisfy the highest ethical standards. 
  
Publication 15. Ensure the right of all researchers associated with the partnership to publish. 
 16. Disseminate all research results at the conclusion of collaborative studies in a timely fashion. 
 17. Ensure authorship follows ICMJE guidelines. 
 
Social, Scientific, and 
Industrial Value 
18. Maintain competitive advantage in the specified research domains. 
19. Structure the research to maximize potential benefit for communities and society. 
 20. Structure the partnership to have the best chance of benefiting both partners and harming neither. 
  
Transparency 21. Widely publicize the partnership agreement and collaborative opportunities to the public and employees. 
 22. Establish procedures for frequent and effective communication between partners. 
 23. Ensure both partners are aware of other partnerships each may be involved in. 
  
Table 1. 
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I. Background and Introduction 
 
In 2012, the Regenstrief Institute and Merck entered into a 5-year partnership with the goal of 
improving “the health of patients through data analytics, health care innovation, education and 
research that supports evidence-based health care.”1 
In March of 2013, the IU Center for Bioethics (IUCB) received a Request for a Proposal from 
Dr. William Tierney, President/CEO of the Regenstrief Institute to formally evaluate the current 
Merck-Regenstrief partnership with the expectation that it be done on an annual basis, and the 
results be published in the peer reviewed literature. The goal of this evaluation was to provide 
substantive actionable recommendations to minimize the risk that potential or actual conflicts of 
interest in the Merck-Regenstrief partnership would adversely affect the scientific processes and 
outcomes of the partnership. In so doing it would be further expected that the Merck-Regenstrief 
partnership would become a model for other public-private collaborations. 
An initial proposal for the review was submitted on October 6, 2013. A revised version of the 
proposal focusing only on Regenstrief’s activity in the partnership was resubmitted on December 
9, 2013, and subsequently accepted. 
The IUCB review consisted of the following elements: 
1. The development of principles and benchmarks for ethically credible academic-industry 
partnerships. This involved :    
a. An assessment of key documents including:  the Merck-Regenstrief Master 
Collaboration Agreement, an investigator guide to the partnership (“Handbook for 
the Merck-Regenstrief Collaboration”) and an internal report of investigator and 
staff experiences in the first year of the partnership (“Summary of Year-End 
Interviews of Regenstrief Participants in the Merck Collaboration, Year 1”). 
b. A comprehensive literature review of academic-industry collaborations.2 
c. Convening a focus group with the members of Regenstrief’s steering and 
operations committees for the partnership. 
2. A survey of Regenstrief investigator attitudes, experiences, and perspectives about the 
partnership. 
3. A final report to include recommendations.  
This report constitutes Deliverable #2 as outlined in the accepted proposal. 
 
 
 
1 Merck Press Release, “Merck and Regenstrief Institute establish evidence-based care collaboration.” November 8, 
2012 
2 This document was previously submitted as Deliverable #1 
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II. Development of Benchmarks for Ethically Credible Academic-Industry Partnerships 
 
The IUCB constructed a set of principles and benchmarks for ethically credible academic-
industry partnerships meant to be the primary tool for the review (Appendix 1, pg. 45). These 
benchmarks enabled a holistic review of the partnership and provided a common framework for 
conducting the focus group, crafting the investigator survey instrument, conducting the 
retrospective analysis of relevant findings, and making final recommendations.  
In addition to the purposes of this review, these benchmarks have been designed so that 
Regenstrief can apply them to their ongoing partnership with Merck as a set of standards against 
which actions and policies can be assessed, and used on a regular basis as part of any internal 
program evaluation. Furthermore, Regenstrief can apply the benchmarks to future partnerships 
that it enters into with other organizations. 
Along with a memorandum, these benchmarks were presented as Deliverable #1 to Dr. William 
Tierney, President/CEO of Regenstrief Institute, and Dr. Jon Duke, Regenstrief Director of the 
Merck-Regenstrief Partnership, on December 30, 2013, for comment. 
In what follows is a detailed description of the initial stages of the review and how the principles 
and benchmarks were created.   
A. Initial Assessment of Merck-Regenstrief Collaboration Agreement and other Key Documents 
In order to build the knowledge necessary for this review, the IUCB requested copies of the 
Merck-Regenstrief Master Collaboration Agreement and other key documents so as to 
understand, in detail, the nature of the relationship, the commitments made by the partners, what 
expectations were created, what benefits are expected to flow to each partner, and how the 
partnership is managed. These documents were distributed to the authors of this report in early 
October and everyone was asked to read them.  
B. Literature Review of Academic-Industry Collaborations 
An initial search of the literature on ethical issues in academic-industry collaborations was 
conducted by IUCB research assistant, Avril Rua in mid-2013, and then updated by a second 
RA, Joshua Rager in late 2013. These papers were identified through OVID Medline using the 
Medical Subject Headings (MeSH terms):  
Industry AND Academies and Institutes/or Universities AND Cooperative Behavior 
AND Ethics  
Other searches were conducted by adding and combining “Conflict of Interest,” “Academic 
Medical Centers,” “Private-Public Sector Partnerships,” “Drug industry,” and “model[text 
word]” in various combinations. Google Scholar and PubMed searches were conducted using 
similar keyword searches.  
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Papers were selected based on publication year, relevant content, and journal of publication. In 
total, 29 papers were selected. Each IUCB investigator read a set of the papers gathered and 
reported in weekly meetings on their usefulness for creating the benchmarks.  
These papers were also read by IUCB research assistants Avril Rua Pitt and Joshua Rager, 
annotated, and then compiled into an annotated bibliography. The citations in the annotated 
bibliography are organized by their content relevance to each principle. The annotation that 
follows each citation includes the paper’s key argument and the relevant findings and 
conclusions for industry-academia partnerships (Appendix 2, pg. 48). 
It is noteworthy that while a somewhat robust literature exists on academic-industry relationships 
generally, it focuses mostly on those arrangements where industry supports academic researchers 
and where the principal ethical issue is conflict of interest.  A much smaller literature can be 
found that focuses on arrangements of the kind Regenstrief is now beginning to engage in with 
industry, i.e., as collaborative partners. This annotated bibliography reflects these developments.  
C. Creation of Principles and Benchmarks  
Principles can be  ubiquitous concepts in bioethics and are meant to be general action guides for 
ethical behavior and policy. Nonetheless, stand-alone principles do not provide specific guidance 
for every situation without some degree of interpretation and specification.  In contrast, 
benchmarks are more granular and less abstract than principles and serve as achievable metrics 
for satisfying goals. The use of  principles and their corresponding benchmarks is a relatively 
recent addition to the bioethics toolbox and is adapted from Emanuel et al.3 In this format 
benchmarks confirm the extent to which a principle is satisfied. With these concepts in mind, the 
principles and benchmarks of ethically credible partnerships have been designed and written with 
the intention to: 
• establish a practical and achievable floor for partnerships of this kind; 
• provide more direct guidance than principles alone in applying this document;   
• allow considerable freedom to accommodate the variety ways an individual benchmark 
may be achieved. 
 
In addition to the benchmarks, descriptions of the principles are given (Appendix 1, pg. 45) and 
the  methodology used to create them. 
1. Method 
At the conclusion of our initial literature search, items such as exemplars, best practices, 
challenges, and suggestions for academic-industry partnerships were gathered from three 
sources: (1) the literature cited in the annotated bibliography, (2) admirable items within the 
3 Emanuel EJ, Wendler D, Grady C, What makes clinical research ethical. JAMA. 2000;283:2701-2711;  Emanuel 
EJ, Wendler D, Killen J, Grady C What Makes Clinical Research in Developing Countries Ethical? The Benchmarks 
of Ethical Research The Journal of Infectious Diseases 2004; 189:930–7 
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Merck-Regenstrief contract, and (3) the expertise of IUCB faculty. These items were compiled 
into one document and transformed into an initial set of 60 original benchmarks. The IUCB 
faculty investigators met 10 times from October 2013 to December 2013 to draft, discuss, refine, 
and add to this original document. This process led to 23 final benchmarks for ethically credible 
academic-industry partnerships. As these benchmarks were being drafted, they were grouped 
according to common themes which were then identified as the 9 principles in the present 
document. 
On December 30, 2013, these benchmarks, along with the annotated bibliography, were 
presented to Drs. Bill Tierney and Jon Duke of Regenstrief. Comments, feedback, and 
suggestions were solicited. Comments were received from Dr. Tierney on February 21, 2014. 
These comments were reviewed and revisions made accordingly in early March 2014. 
D. Focus Group with Regenstrief Leadership of Merck-Regenstrief Partnership 
On March 25, 2014, the IUCB convened a focus group with Regenstrief members of the Steering 
and Operations Committees for the Merck-Regenstrief partnership to understand and assess the 
perspectives of key leaders involved in managing the partnership based on the ethical principles 
and benchmarks of a model collaboration.  
1. Method 
An interview guide (Appendix 3, pg. 56) was drafted by IUCB faculty investigators from 
February 2014 to March 2014 based on the principles and benchmarks document. A current list 
of the Regenstrief leadership in the partnership was obtained from Jennifer Gatz, Managing 
Researcher at Regenstrief, in early March 2014. Prior to convening the focus group, a copy of 
the principles and benchmarks along with a study information sheet were emailed to participants 
on March 11, 2014. A second email with the same attachments was sent to participants on March 
24, 2014 to remind them of the focus group. 
This study was determined to be exempt by the IU IRB (Study #1401404759). Taping and note 
taking occurred throughout the session. Recordings were uploaded and sent for transcription to 
The Processed Word (www.mdtheprocessedword.com). Transcriptions were received on 
Monday, March 31, 2014 and cleaned for errors (See Appendix 4 for key quotes from transcript, 
pg. 61). The transcripts were then read and analyzed for content and pertinence to the 
benchmarks. 
2. Outcomes  
Five representatives of the Regenstrief steering and operations committees participated in the 
focus group. Representation included: 3 members of the operations committee, 1 member of the 
steering committee, and 1 participant who served on both the steering and operations 
committees. There was one invitee who was not in attendance. The session lasted 2 hours. 
Further analysis of the focus group will occur in Section IV. 
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III. Survey of Regenstrief Research Scientists and Affiliated Scientists 
To better understand the experiences, knowledge, and perspectives of Regenstrief Research 
Scientists and Affiliated Scientists, we designed and implemented an online survey using 
RedCap consisting of 30 questions that used a 6-point Likert scale. Several questions permitted 
free-text responses. 
1. Method 
At the conclusion of the focus group in late March, the IUCB began drafting a survey instrument 
based on the benchmark document and results of the focus group. From April 2014 to June 2014, 
involved members of the IUCB met 9 times to create, draft, and edit the survey instrument. The 
instrument was reviewed by internal expert, Dr. Aaron Carrol, Director of the IU Center for 
Health Policy and Professionalism Research, and he offered comments and suggestions. Email 
addresses (e.g., Listservs) of eligible Regenstrief participants were obtained from Jennifer Gatz.  
Prior to our request to participate, potential participants were sent an email from William 
Tierney, CEO/President of Regenstrief, encouraging their participation. On July 10, 2014, all 
potential participants were sent an email containing a study information sheet, a request for their 
participation, and a link to the online survey. Reminders were sent to potential participants on 
July 16, 2014, and July 22, 2014. The survey closed on July 28, 2014. This study was deemed 
exempt by the IU IRB (Study #1406322622). 
2. Results  
93 Regenstrief research scientists and affiliated scientists were invited to participate in the survey 
and we received 35 partial or complete records for a response rate of 38%. To count as a record, 
the respondent must have answered at least one question beyond the first four demographic 
questions (Appendix 5, pg. 73). Of the total 93 invited to participate, 51 were identified as 
research scientists and 42 as affiliate scientist. We received 26 research scientist records and 9 
affiliate records for response rates among these two groups of 51% and 21%, respectively. 
Additionally, of those records received, 8 reported having been supported by the partnership and 
27 having never been supported.  
3. Method for Interpreting Results 
We used a color-coding system (as seen above in the results section) to identify responses 
suggesting: 
• good or acceptable achievement (GREEN); 
• caution or attention (YELLOW); 
• notable concern and needed attention (RED). 
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To identify and classify these areas we used the rubric below: 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
GREEN 61%-100% 0-30% 0-10% 
YELLOW 31%-60% 31%-60% 11%-20% 
RED 0%-30% 61%-100% 21%-100% 
 
Some questions were intentionally written as negative statements, i.e., statements which, 
according to the benchmarks, one would not want to see high rates of agreement (Questions 10, 
13, 14, 22, 23). In these cases, the percentage criteria for the strongly agree/agree and strongly 
disagree/ disagree columns would switch to determine which color and category it should 
receive. For example, in Question 23 we stated “I feel there is a conflict between my professional 
goals and the goals of the partnership.” Guided by notions of conflict of commitment and the 
principle “Conflict of Interest Policy and Management,” we would not want to see a high 
percentage of respondents agreeing with this statement. In this instance, 67% of respondents 
either disagreed or strongly disagreed with statement and only 3% either agreed or strongly 
agreed with this statement. As such, the 67% satisfies the Green criterion for strongly 
agree/agree and the 3% for the Green criterion in strongly disagree/disagree which suggests good 
or acceptable achievement. 
Other questions do not lend themselves to strict use of this rubric (Questions 1 and 24). In these 
instances, the possible responses (e.g., knowledgeable, somewhat knowledgeable) are grouped 
according to what has been deemed appropriate by the authors of this report and then the rubric 
is applied. 
4. Results for Each Question. 
 Q1: In your opinion, how knowledgeable are you of the Merck-Regenstrief partnership? (due to 
a computer glitch, the first 12 records did not contain this question) 
 VERY 
KNOWLEDGEABLE 
KNOWLEDGEABLE SOMEWHAT NOT 
TOTAL N=27 4 (15%) 5 (19%) 12 (44%) 6 (22%) 
 AT LEAST SOMEWHAT KNOWLEDGEABLE NOT 
 21 (78%) 6 (22%) 
 
Q2: The Merck Regenstrief partnership has an acceptable data sharing policy. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=35) 12 (34%) 23 (66%) 0% 
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Q3: The Merck-Regenstrief partnership is likely to benefit society. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=33) 24 (71%) 10 (29%) 0% 
 
Q4: The Merck Regenstrief partnership ensures that all Regenstrief investigators are given equal 
opportunity to submit proposals for funding in the partnership. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 15 (43%) 16 (46%) 4(11%) 
 
Q5: The Merck-Regenstrief partnership chooses research areas of focus that prioritize Merck’s 
interests. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=35) 15 (43%) 20 (57%) 0% 
 
Q6: The Merck-Regenstrief partnership adequately protects investigators’ intellectual property 
rights. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=35) 7 (20%) 28 (80%) 0% 
 
Q7: The Merck-Regenstrief partnership promotes investigator-initiated science. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=35) 14 (40%) 17 (49%) 4 (11%) 
 
Q8: The Merck-Regenstrief partnership is beneficial to Regenstrief. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=35) 27 (77%) 8 (23%) 0% 
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 Q9: The Merck-Regenstrief partnership effectively disseminates the funding opportunities to all 
investigators who are eligible to apply 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=35) 12 (34%) 16 (46%) 7 (20%) 
 
Q10: The Merck-Regenstrief partnership chooses research areas of focus in ways that are 
problematic. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=35) 2 (6%) 24 (69%) 9 (25%) 
 
Free response: 
“funds projects not likely to be funded by traditional government or foundation sources” 
“focus on evidence from practice such as NLP applications in clinical text “ 
Q11: The Merck-Regenstrief partnership permits investigators to continue on-going 
collaborations with other research collaborators or teams. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 18 (53%) 16 (47%) 0% 
 
Q12: The Merck-Regenstrief partnership is likely to benefit patients. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 18 (53%) 16 (47%) 0% 
 
Q13: The Merck-Regenstrief partnership pressures faculty to work outside of their own research 
interests. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 1 (3%) 17 (50%) 16 (47%) 
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Q14: The Merck-Regenstrief partnership results in the exploitation of students and fellows. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=32) 1 (3%) 15 (47%) 16 (50%) 
 
Q15: The Merck-Regenstrief partnership explains the procedures for applying for funding to all 
eligible investigators. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 14 (41%) 14 (41%) 6 (18%) 
 
Q16: The Merck-Regenstrief partnership chooses research areas of focus that prioritize 
Regenstrief’s interests. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 9 (26%) 21 (62%) 4 (12%) 
 
Q17: The Merck-Regenstrief partnership has established clear criteria for which projects will be 
funded. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 5 (15%) 22 (64%) 7 (21%) 
 
Q18: The Merck-Regenstrief partnership has been beneficial to me 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 8 (24%) 14 (41%) 12 (35%) 
 
Free response for those who selected strongly agree/agree: 
“I acquired salary support, new collaborators, and a mechanism to pursue science related to my 
goals.” 
“Projects chosen are priorities for Merck and RI so will benefit me directly or indirectly” 
“Both support &opportunity to pursue meaningful collaborations” 
“I am receiving support for my research.” 
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“Has helped, in part, advance Gopher and OpenMRS” 
“funding, publications, collaborations” 
“Funding, furthering my interests, well run and organized” 
“Funding received has benefited my specific area of research, which is of general interest to 
Merck but allows me to specifically pursue an area not yet recognized/funded by other agencies. 
With this support we have been able to collect valuable pilot data and collaborate with pharma 
scientists to further understand/promote the research area.” 
Free response for those who selected strongly disagree/disagree: 
“It hasn't negative affected me it just hasn't affected me in anyway that I am aware of” 
“no negative impact, just no beneficial impact” 
“Has not been of direct benefit to me and has contributed to the strain between the IUSM and RI. 
It may have created conflicts of interest or conflicts of commitment that bring into question how 
the relationship with Merck is helping RI's role as a support organization to the School of 
Medicine (as opposed to serving primarily RI's needs more directly).” 
“I am new to Regenstrief Institute and do not have sufficient knowledge about the Merck-
Regenstrief partnership.” 
QUESTIONS 19-21 ONLY AVAILABLE TO THOSE WHO STRONGLY 
AGREED/AGREED IN QUESTION 8 
Q19: Partnering with Merck has benefitted Regenstrief by providing more research funding 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=25) 25 (100%) 0% 0% 
 
Q20: Partnering with Merck has benefitted Regenstrief by creating an environment more 
supportive to partnering with outside entities. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=25) 23 (92%) 2 (8%) 0% 
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Q21: Partnering with Merck has benefitted Regenstrief by creating a more effective system for 
managing projects. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=25) 8 (32%) 12 (48%) 5 (20%) 
 
Q22: I have concerns that some projects conducted in the partnership are unethical. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=34) 0% 12 (35%) 22 (65%) 
 
Q23: I feel there is a conflict between my professional goals and the goals of the partnership. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=33) 1 (3%) 10 (30%) 22 (67%) 
 
Q24: The Merck-Regenstrief partnership has had the following effect on my ability to compete 
for research funding. 
 STRENGTHENED NEITHER WEAKENED DON’T KNOW 
TOTAL (N=33) 8 (24%) 25 (76%) 0% 0% 
 STRENGTHENED/ NEITHER WEAKEND/ DON’T KNOW 
 33 (100%) 0% 
 
REST OF QUESTIONS ONLY AVAILABLE TO THOSE WHO REPORTED HAVING 
BEEN SUPPORTED 
Q25: The Merck-Regenstrief partnership has effective mechanisms to manage conflicts of 
interest. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=7) 3 (43%) 3 (43%) 1 (14%) 
 
Q26: The Merck-Regenstrief partnership ensures the right of all investigators to publish. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=7) 6 (86%) 1 (14%) 0% 
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Q27: The Merck-Regenstrief partnership encourages timely dissemination of research results. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=7) 5 (71%) 2 (29%) 0% 
 
Q28: There is effective communication between Regenstrief and Merck co-investigators. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=7) 5 (72%) 1 (14%) 1 (14%) 
 
Q29: My right to publish research findings from my work in the partnership does not differ from 
my right to publish from my work on other projects. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=7) 6 (86%) 0% 1 (14%) 
 
Q30: The projects I’ve been involved in the partnership are undertaken according to the highest 
ethical standards. 
 STRONGLY 
AGREE/AGREE 
NEITHER/ I DON’T 
KNOW/ NA 
STRONGLY 
DISAGREE/DISAGREE 
TOTAL (N=7) 7 (100%) 0% 0% 
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IV. Findings 
A. Specific Findings 
1. Method 
Survey results were used to assess whether Regenstrief met a benchmark or not.   
We used a rough three-part distinction in making what is a somewhat subjective assessment: 
• To conclude that a benchmark has been MET, we required that greater than or equal to 
50% of respondents to the questions relating to that benchmark Agreed or Strongly 
Agreed.  
• To conclude that a benchmark has NOT BEEN MET, we required that less than 30% of  
respondents to the questions relating to that benchmark Agreed or Strongly Agreed.   
• To conclude that the JURY’S OUT on whether a  benchmark has been met we required 
that between greater than 30% and up to 49% Agreed or Strongly Agreed.  
 
 STRONGLY 
AGREE/AGREE 
MET ≥ 50% 
NOT MET < 30% 
JURY’S OUT 30% - 49% 
 
Instances where the questions are posed as negative statements (i.e., the opposite of a 
benchmark, Questions 10, 13, 14, 22, 23), we would want to see ≥ 50% of strongly 
disagree/disagree. To keep the graphs visually consistent, the color green is used for strongly 
disagree/disagree for these questions. 
There were also cases where the benchmark was not appropriate to include in the investigator 
survey. This occurred when the benchmark pertained to an organizational- or systems-level 
policy or partnership arrangement that investigators would not be expected to know. In these 
situations, a consensus opinion of the research team was employed to determine whether the 
benchmark had been met or not. 
There are also instances where one benchmark has multiple questions that inform whether or not 
the benchmark has been met. In some case, both questions suggest the benchmark has been MET 
but in others, the responses suggest varying levels of achievement. In the case of the latter 
situation, a paragraph follows both graphs describing what weight is given to each question. 
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BENCHMARK 1: Promote investigator-initiated science and protect the ability of investigators 
to attract and maintain federal research support. 
 
• Jury’s Out: Benchmark has not been clearly MET or NOT MET 
• 49% Neither Agree Nor Disagree or Don’t Know/NA 
• 11% Disagree or Strongly Disagree 
 
 
• Benchmark MET 
Given these two pieces of information, we believe that the JURY’S OUT for Benchmark #1. We 
make this conclusion because while we found the responses to Question 24 in accordance with 
the benchmark, only 40% of respondents agreed or strongly agreed with Question 7 and a small 
but significant number of respondents (4) disagreed or strongly disagreed with the statement in 
Question 7. The greater weight we gave to Question 7 over Question 24 in this case is based on 
our sense that the component of benchmark #1 covered in question 24 simply asks for 
noninterference from partnership—a negative right of sorts—whereas the component addressed 
40% 
49% 
11% 
Question 7: The Merck-Regenstrief partnership promotes 
investigator-initiated science.  
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
100% 
Question 24: The Merck-Regenstrief partnership has had the 
following effect on my ability to compete for research funding. 
STRENGTHENED/NEITHER
WEAKENED/ DON'T KNOW
N=35 
N=33 
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by Question 7 requires more of the partnership to ensure and promote investigator-initiated 
science. 
 BENCHMARK 2: Permit investigators to initiate or continue collaboration with any other 
qualified group, person, or entity. 
.  
• Benchmark MET 
 
BENCHMARK 3: Ensure that all investigators involved in the partnership are given equal 
opportunity to submit proposals for funding. 
 
• Jury’s Out: Benchmark has not been clearly MET or NOT MET 
• 46% of  respondents Neither Agree Nor Disagree or Don’t Know/NA 
• 11% disagree or strongly disagree 
 
53% 
47% 
Question 11: The Merck-Regenstrief partnership permits 
investigators to continue on-going collaborations with other 
research collaborators or teams. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
43% 
46% 
11% 
Question 4: The Merck Regenstrief partnership ensures that all 
Regenstrief investigators are given equal opportunity to submit 
proposals for funding in the partnership 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=34 
N=34 
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BENCHMARK 4: Avoid obligating faculty to work outside their own self-defined scientific 
area 
 
• Jury’s Out: Benchmark has not been clearly MET or NOT MET  
• 50% of  respondents Neither Agree Nor Disagree or Don’t Know/NA 
 
BENCHMARK 5: Protect students, fellows, and post-doctoral fellows involved in 
collaborative projects from exploitation. 
 
• Benchmark MET 
• However, 47% of  respondents Neither Agree Nor Disagree or Don’t Know/NA 
 
 
3% 
50% 
47% 
Question 13: The Merck-Regenstrief partnership pressures 
faculty to work outside of their own research interests.  
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
3% 
47% 
50% 
Question 14: The Merck-Regenstrief partnership results in the 
exploitation of students and fellows. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=34 
N=35 
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BENCHMARK 6: Ensure that effective mechanisms exist to eliminate, control, or manage 
conflicts of interest in the partnership. 
 
• Jury’s Out: Benchmark has not been clearly MET or NOT MET  
• 43% of  respondents Neither Agree Nor Disagree or Don’t Know/NA  
• 14% of respondents disagree or strongly disagree. 
• Notable that this question was only asked of those who have been supported by the 
partnership. 
 
BENCHMARK 7: Ensure all investigators and both partners retain their proprietary and 
intellectual property rights throughout and after the partnership. 
 
• Benchmark NOT MET 
• 80% of  respondents Neither Agree Nor Disagree or Don’t Know/NA 
 
43% 
43% 
14% 
Question 25: The Merck-Regenstrief partnership has effective 
mechanisms to manage conflicts of interest. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
20% 
80% 
Question 6: The Merck-Regenstrief partnership adequately 
protects investigators’ intellectual property rights. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=7 
N=35 
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BENCHMARK 8: Ensure that data arrangements are explicit and that all rights to access 
data are fairly negotiated at the outset of the partnership. 
 
• Jury’s Out: Benchmark has not been clearly MET or  NOT MET  
• 66% of  respondents Neither Agree Nor Disagree or Don’t Know/NA 
 
BENCHMARK 9: Establish parameters for what type of projects will and will not be 
funded (e.g., add-on projects, training, pilot studies). 
 
• Benchmark NOT MET 
• 64% of  respondents Neither Agree Nor Disagree or Don’t Know/NA 
• 21% of respondents disagree or strongly disagree 
 
34% 
66% 
Question 2: The Merck Regenstrief partnership has an 
acceptable data sharing policy 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
15% 
64% 
21% 
Question 17: The Merck-Regenstrief partnership has 
established clear criteria for which projects will be funded.  
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=35 
N=34 
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BENCHMARK 10: Create ways to protect each party from an unexpected end to the 
partnership. 
No survey data were sought. We did not ask investigators about procedures in the event of a 
premature dissolution of the partnership given such decisions would made by leadership and not 
investigators. However, given that each section of the collaboration agreement contains formal 
procedures for early termination of the contract, we can reasonably conclude that this benchmark 
has been satisfactorily met.  
BENCHMARK 11: Assess formally the efficiency, effectiveness, and achievements of the 
partnership on an annual basis. 
No survey data were sought. We did not ask investigators about formal review of the partnership 
given that such a benchmark is established primarily for partnership leadership. However, by 
virtue of this report, we can reasonably conclude that this benchmark has been satisfied. 
 
BENCHMARK 12: Ensure that clear, comprehensive, and efficient procedures exist for all 
governance entities of the partnership and are known to all investigators. 
  
• Benchmark NOT MET 
• 69% of respondents Neither Agree nor Disagree or Don’t Know/ NA: 
 
6% 
69% 
25% 
Question 10: The Merck-Regenstrief partnership chooses 
research areas of focus in ways that are problematic. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=35 
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• Jury’s Out: Benchmark has not been clearly MET nor  NOT MET  
• 41% of respondents Neither Agree Nor Disagree or Don’t Know/NA 
• 18% of respondents disagree or strongly disagree 
 
Given these two pieces of information, we conclude that the benchmark has NOT been met given 
the responses to Question 10 but also because 59% of respondents to Question could not confirm 
that the partnership explains the procedures for applying for funding to all eligible investigators. 
 
BENCHMARK 13: Ensure that all investigators, staff, and other participants in the 
partnership have adequate training in the responsible conduct of research and related 
ethical issues. 
 
• Benchmark MET 
41% 
41% 
18% 
Question 15: The Merck-Regenstrief partnership explains the 
procedures for applying for funding to all eligible investigators.  
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
35% 
65% 
Question 22: I have concerns that some projects conducted in 
the partnership are unethical. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=34 
N=34 
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BENCHMARK 14: Ensure that all projects in the partnership aim to satisfy the highest 
ethical standards. 
 
• Benchmark MET 
• Notable that this question was only asked to those that have been supported by the 
partnership. 
 
BENCHMARK 15: Ensure the right of all researchers associated with the partnership to 
publish. 
 
• Benchmark MET 
• Notable that this question was only asked to those who have been supported by the 
partnership 
 
100% 
Question 30: The projects I’ve been involved in the partnership 
are undertaken according to the highest ethical standards. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
86% 
14% 
Question 26: The Merck-Regenstrief partnership ensures the 
right of all investigators to publish. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=7 
N=7 
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• Benchmark MET 
• Notable that this question was asked only to those who have been supported by the 
partnership 
 
BENCHMARK 16: Disseminate all research results at the conclusion of collaborative 
studies in a timely fashion. 
 
• Benchmark MET 
 
 
 
86% 
14% 
Question 29: My right to publish research findings from my 
work in the partnership does not differ from my right to 
publish from my work on other projects. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
71% 
29% 
Question 28: The Merck-Regenstrief partnership encourages 
timely dissemination of research results.  
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=7 
N=35 
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BENCHMARK 17: Ensure authorship follows ICMJE guidelines. 
No survey data were sought.. Additionally, there isn’t any evidence in the documents we’ve been 
provided with that suggest publications resulting from the partnership follow these guidelines. 
Given that journals require these authorship guidelines be followed, we assume but cannot 
confirm or disconfirm that the benchmark has been met. Inconclusive findings. 
BENCHMARK18: Maintain competitive advantage in the specified research domains. 
 
• Benchmark MET 
 
BENCHMARK 19: Structure the research to maximize potential benefit for communities 
and society. 
 
• Benchmark MET 
100% 
Question 24: The Merck-Regenstrief partnership has had the 
following effect on my ability to compete for research funding. 
STRENGTHENED/NEITHER
WEAKENED/ DON'T KNOW
71% 
29% 
Question 3: The Merck-Regenstrief partnership is likely to 
benefit society. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=33 
N=33 
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• Benchmark MET 
 
Both questions suggest the benchmark has been MET and so we conclude that the benchmark 
has been MET. 
BENCHMARK 20: Structure the partnership to have the best chance of benefiting both 
partners and harming neither.  
 
• Benchmark NOT MET 
• 41% of respondents Neither Agree nor Disagree or Don’t Know/NA 
• 35% of respondents disagree or strongly disagree with the statement 
 
 
53% 
47% 
Question 12: The Merck-Regenstrief partnership is likely to 
benefit patients. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
24% 
41% 
35% 
Question 18: The Merck-Regenstrief partnership has been 
beneficial to me. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=34 
N=34 
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• Benchmark MET 
 
Despite the fact that the responses to Question 18 suggest that the benchmark has not been met, 
free responses to this question indicate that while some investigators may not directly benefit 
from the partnership, investigators indicated that it neither harmed them as well: 
“It hasn't negative affected me it just hasn't affected me in anyway that I am aware of” 
“no negative impact, just no beneficial impact” 
As can be seen in the survey instrument (Appendix 5, pg. 73), we asked respondents that if they 
disagree or strongly disagree with the statement in Question 18 but felt the partnership didn’t 
harm with either, to leave the free response blank. Only one respondent indicated being harmed 
but even in this response, the harm appears to be less individual and more institutionally-minded: 
“Has not been of direct benefit to me and has contributed to the strain between the IUSM and RI. 
It may have created conflicts of interest or conflicts of commitment that bring into question how 
the relationship with Merck is helping RI's role as a support organization to the School of 
Medicine (as opposed to serving primarily RI's needs more directly).” 
However, given the available responses, we reasonably conclude that this benchmark has been 
MET.  
 
 
 
 
77% 
23% 
Question 8: The Merck-Regenstrief partnership is beneficial to 
Regenstrief.   
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=35 
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BENCHMARK 21: Widely publicize the partnership agreement and collaborative 
opportunities to the public and employees. 
 
• Jury’s Out: Benchmark has not been clearly MET nor  NOT MET  
• 46% of respondents Neither Agree nor Disagree or Don’t Know/NA 
• 20% of respondents disagree or strongly disagree with the statement 
 
 
BENCHMARK 22: Establish procedures for frequent and effective communication 
between partners. 
 
• Benchmark MET 
 
 
34% 
46% 
20% 
Question 9: The Merck-Regenstrief partnership effectively 
disseminates the funding opportunities to all investigators who 
are eligible to apply 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
72% 
14% 
14% 
Question 28: There is effective communication between 
Regenstrief and Merck co-investigators. 
STRONGLY AGREE/AGREE
NEITHER/ I DON’T KNOW/ NA 
STRONGLY DISAGREE/ DISAGREE
N=35 
N=7 
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BENCHMARK 23: Ensure both partners are aware of other partnerships each may be 
involved in. 
No survey data were sought. Additionally, there isn’t any evidence in the documents we’ve been 
provided with that suggest each partner knows of other formal partnerships the partner may be 
engaged in. However, this lack of evidence does not confirm the benchmarks has not been met 
but simply there isn’t any evidence suggesting one way or the other. Inconclusive findings. 
B. General Findings 
We compiled the raw data from each question according to the principle that is associated with 
its analogous benchmark to ascertain general findings. To determine whether or not the principle 
has been MET, NOT MET, or JURY’s OUT we used the following thresholds: 
 POSITIVE 
MET ≥ 50% 
NOT MET < 30% 
JURY’S OUT 30% - 49% 
 
The term positive means the response is in agreement with the given benchmark. 
 
ACADEMIC FREEDOM 
 
• Principle MET 
 
 
 
56% 
39% 
5% 
Academic Freedom 
POSITIVE
NEUTRAL
NEGATIVE
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CONFLICT OF INTEREST POLICY AND MANAGEMENT 
 
• Principle MET 
 
 
DATA SHARING AND ACCESS 
 
• Jury’s Out: Principle has not been clearly MET or NOT MET 
 
 
 
 
57% 
39% 
4% 
Conflict of Interest Policy and Management 
POSITIVE
NEUTRAL
NEGATIVE
34% 
66% 
Data Sharing and Access 
POSITIVE
NEUTRAL
NEGATIVE
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INTELLECTUAL PROPERTY 
 
 
 
EFFECTIVE GOVERNANCE 
 
• Jury’s Out: Principle has not been clearly MET nor  NOT MET  
• 52% of respondents gave responses that were neutral towards effective governance 
concerns  
 
34% 
52% 
14% 
Effective Governance 
POSITIVE
NEUTRAL
NEGATIVE
 
• Principle NOT MET 
20% 
80% 
Intellectual Property 
POSITIVE
NEUTRAL
NEGATIVE
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PROTECTION OF HUMAN SUBJECTS 
 
• Principle MET 
 
 
 
PUBLICATION 
 
• Principle MET 
 
 
 
71% 
29% 
Protection of Human Subjects 
POSTIVE
NEUTRAL
NEGATIVE
81% 
14% 
5% 
Publication 
POSITIVE
NEUTRAL
NEGATIVE
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SOCIAL, SCIENTIFIC AND INDUSRIAL VALUE 
 
• Principle MET 
 
 
 
TRANSPARENCY 
 
• Jury’s Out: Benchmark has not been clearly MET nor  NOT MET 
 
 
 
50% 
40% 
10% 
Social, Scientific, and Industrial Value 
POSITIVE
NEUTRAL
NEGATIVE
41% 
40% 
19% 
Transparency 
POSITIVE
NEUTRAL
NEGATIVE
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A. Summary of Findings 
Of the 23 benchmarks, we concluded that  
• 12 have BEEN MET (Benchmarks #2, 5, 10, 11, 13, 14, 15, 16, 18, 19, 20, 22), 
•  4 have NOT BEEN MET (Benchmarks #7, 8, 9, 12), and  
• 6 benchmarks, the JURY’S OUT (Benchmarks #1, 3, 4, 6, 21).  
• 4 were not applicable to the survey format, but based on the research team’s consensus 
opinion,  
o 2 benchmarks have BEEN MET (Benchmarks #10, 11)  
o 2 benchmarks, the JURY’S OUT (Benchmarks #17, 23).  
Of the 9 principles, we found that 
• 5 have BEEN MET (Academic Freedom; Conflict of Interest Policy and Management; 
Protection of Human Subjects; Publication; Social, Scientific, and Industrial Value), 
•  2 have NOT BEEN MET (Intellectual Property; Data Sharing and Access),  
• 2 principles the JURY’S OUT (Effective Governance; Transparency).  
Included in Appendix 6 (pg. 76) is a visual summary/“report card” of these results. 
B. Limitations. 
1. The response rate of 38% was low, as were the number of survey participants making it 
difficult to report these results as representative of all Regenstrief Scientists and 
Affiliates. 
2. The standards for determining whether a benchmark or principle was met, not met, or 
jury’s out was subjective to a great extent. That said, raising the percentage of 
agree/strongly agree to 60%, 75%, 95% (for example) as the standard by which a 
benchmark was met;  or lowering  the percentage of agree/strongly agree to 25%, 20% or 
10% (for example) as the standard by which a benchmark was assessed to have not been 
met would have changed the results dramatically. 
3. The method for determining whether a principle was met, not met, or jury’s out may have 
been skewed due to the varying number of respondents among the questions. Thus, 
whether or not a principle was met was largely determined by the responses given in 
questions with the greatest number of respondents.  
4. Despite the conceptual relevance, the heterogeneity of the questions and benchmarks that 
fall under a given principle means that the results of aggregating the data by principles 
should be interpreted loosely and used only as a baseline for a future review. At times, 
this also produced what seems to be a qualitative disparity in the specific findings and 
general findings.     
5. These results are based almost exclusively on how Regenstrief investigators think the 
partnership matches up with the principles and benchmarks for ethically credible 
partnerships. As such, what may otherwise be achievement in a benchmark given only 
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data from the contract and key leadership informants, this review relied on the attitudes 
and perspectives—however informed—of Regenstrief investigators to judge the 
partnership based on our standards.  
6. The relative uniqueness of this partnership (e.g. bioinformatics-based, Regenstrief as a 
support organization to the IU School of Medicine) means that this review and the 
standards used to judge it may be idiosyncratic, thus questioning generalizability to other 
academic-industry partnerships.  
7. In times where no survey data was not sought, the writers of this report used consensus to 
determine whether the benchmark had been met or not. This is a subjective measure 
based only on internal discussion and what evidence was available to us.   
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V. Recommendations 
Based on these findings, we make the following recommendations: 
 Recommendation #1: Increase transparency by providing more opportunities for 
investigators to become educated about the partnership, especially in areas where lack of 
understanding could potentially lead to an erosion of trust among Regenstrief investigators.  
The areas of notable concern for this recommendation include Benchmarks #7 and 8. While there 
is evidence in the contract that these principles and benchmarks have been addressed, it is 
imperative that investigators know how intellectual property is protected and awarded in 
partnership projects and also, the agreed upon terms for data use by Merck in partnership 
projects. Additionally, other benchmarks that we found to have been NOT MET or for which the 
JURY’S OUT (Benchmarks #1, 2, 4, 6, 9, 12, 21) included high rates of no opinion or little 
knowledge on the matter. As such, education in these areas may ameliorate these issues. 
We imagine that this can be achieved in a number of ways: 
• In addition to the handbook that emailed to all eligible investigators, Regenstrief could 
hold an annual meeting where projects recently completed or being conducted in the 
partnership are reported to all investigators. This could spur interest in the partnership 
and also correct misinformed opinions about the partnership. 
• At the conclusion of this review, hold a “town hall” meeting where these results could be 
presented to Regenstrief investigators and leadership would be able to provide 
information where seemingly problematic issues arise and investigators could further 
elaborate on the identified areas. 
• At the conclusion of this review, write a memorandum of the findings joined with 
educational information on the partnership to be sent to all Regenstrief investigators. 
Recommendation #2: Increase transparency in the project selection process by establishing 
and making explicit to all investigators how projects are selected and what criteria are 
used. 
While Benchmarks #9 and #12 were addressed in Recommendation #1, we feel that these 
benchmarks need specific attention given that they comprise 2 of the 4 benchmarks that were 
NOT MET and that education measures alone may not remedy the issues here. 
We believe that this could be achieved in a number of ways: 
• Providing details about the process, and include it in the investigator handbook for the 
partnership. 
• Allow an unaffiliated and unbiased observer to sit in on the project selection meetings in 
order to form an objective description of the process. This person would ideally be 
qualified to offer recommendations on improving process after seeing how the committee 
selects projects. 
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Recommendation #3: Regenstrief should seek additional ways to engage more investigators 
in the partnership.  
We also found that despite what we feel is a process that lends itself to investigator-initiated 
science, the survey results indicate otherwise. Only 40% of those surveyed agreed or strongly 
agreed with the statement that the partnership promotes investigator-initiated science (Question 
7). Additionally, less than half of respondents disagreed or strongly disagreed with the statement 
that the partnership pressures faculty to work outside their own self-defined research area 
(Question 13).  Notably however, of those surveyed who had been supported by the partnership, 
7 out of 8 either agreed or strongly agreed with the statement in Question 7 and 6 out of 8 
disagreed or strongly disagreed with the statement in Question 13. 
This could be accomplished by: 
• Distinguishing announcements for this call for proposals from all others (e.g., NIH, 
PCORI, etc) so as to draw attention to them in Regenstrief email. 
• Holding an annual Regenstrief WIP on the research outcomes of the partnership and use 
the opportunity to discuss the partnership and the next call for proposals. 
Recommendation #4: In addition to the extant conflict of interest disclosure policies 
required by the IU School of Medicine, Regenstrief should establish and publicize widely 
partnership-specific conflict of interest policies. 
Only 3 of 7 respondents who have been supported by the partnership could confirm that the 
partnership has effective mechanisms to manage conflicts of interest. While this question was not 
posed to the entire population surveyed, we feel that this demographic—by virtue of their 
participation in the partnership—would likely have the best chance of knowing whether or not 
conflicts of interest are effectively managed. Given this data, we make the recommendation 
above. While we feel the existing IU COI policies are sufficient, additional steps taken in this 
area may help to curb or quell a perception that COIs are inherent problems in academia-industry 
partnerships. 
We believe this could be accomplished in a number of ways: 
• Requesting COI self-disclosure from investigators akin to the IU policy when selected 
projects are funded. 
• Requesting COI self-disclosure from investigators akin to the IU policy as a part of the 
initial proposal process. That is, an essential part of the proposal submitting process 
includes disclosing potential conflicts of interest. 
• Issue a join position paper by Regenstrief and Merck on conflicts of interests and 
circulate it to relevant bodies and personnel. 
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Recommendation #5: Regenstrief should continue to reach out to investigators who may 
have concerns about the partnership and provide opportunities for learning, consultation 
and input. 
This could be accomplished in a number of ways: 
• Conduct a more comprehensive assessment of Regenstrief investigator knowledge and 
attitudes about this partnership and other partnerships, which includes one-on-one 
interviews or focus groups. 
• Providing an open and non-threatening opportunity for investigators to express concerns 
about the partnership.  
• Ensure that Regenstrief investigators are aware of and encouraged to make use of the 
CTSI Bioethics and Subject Advocacy Program consultation service.  
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APPENDIX 1 
 
 
 Principles and Benchmarks for Ethically Credible Partnerships 
Principles 
Academic Freedom—refers to researchers, their interests, and their ability to pursue these independent interests as they see fit. 
Conflict of Interest Policy and Management—refers to the competing or potentially competing interests and commitments of involved parties 
and persons, including financial conflicts of interests and conflicts of commitment. Managing such conflicts can be achieved through establishing 
tested methods for assessing potential conflicts of interests.  
Data Sharing, Access— includes the importance of developing mutually agreed upon procedures for accessing each partner’s data and other 
relevant clinical information in order to facilitate research.  
Intellectual Property—this  principle emphasizes the need to protect the property rights of each partner and investigators that predate the 
partnership and arise from work conducted within it.  
Effective Governance—emphasizes the importance of effectively managing and leading the partnership. Governance addresses legal issues, 
administrative duties/obligations, priority setting, and fosters fairness, cooperation, and communication within the partnership. Effective 
governance should be bureaucratically structured in a way that sufficiently leads and enables research and is minimally burdensome. The rules and 
conditions set by and for the partnership’s governance entities would preferably be set at the outset of the collaboration. 
Protection of Human Subjects—establishes that collaborative research should adhere to the highest ethical standards, including compliance with 
applicable standards relating to the privacy and confidentiality of personal health information. 
Publication—focuses on issues of authorship and how research findings are to be published, disseminated, or made known to others. Usually this 
principle can be satisfied through publishing in the peer-reviewed literature. 
Social, Scientific, and Industrial Value—refer collectively to the benefits for and goals of each partner in the collaboration. These include 
industry values, scientific values, medical values, and social values. The partnership should seek to create new knowledge that will improve the 
well-being of citizens and be of significant importance to the academic and industrial partner.  
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Transparency—concerns the degree to which the collaboration is known by and visible to relevant parties and the public including its function 
and initial agreement. Transparency is primarily achieved through open communication.  
 
Definition of Benchmarks 
Benchmarks are specific standards or practices that are used to confirm the extent to which a principle is satisfied.  The benchmark framework is 
adapted from Emanuel et al (2004) and the present draft of benchmarks seeks to establish practical and achievable baselines for Industry-
Academia collaboration while still allowing for considerable freedom as to how they may be achieved. The substance of the benchmarks is pulled 
from the literature on this topic, admirable items within the Regenstrief-Merck contract, and the IU Center for Bioethics’ own experience and 
expertise in policy and ethics. 
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PRINCIPLES        BENCHMARKS 
  
Academic Freedom 1. Promote investigator-initiated science and protect the ability to attract and maintain federal research support. 
 2. Permit investigators to initiate or continue collaboration with any other qualified group, person, or entity. 
 3. Ensure that all investigators involved in the partnership are given equal opportunity to submit proposals for funding. 
 4. Avoid obligating faculty to work outside their own self-defined scientific area. 
 
Conflict of Interest 
Policy and Management 
 
5. Protect students, fellows, and post-doctoral fellows involved in collaborative projects from exploitation. 
6. Ensure that effective mechanisms exist to eliminate, control or manage conflicts of interest in the partnership. 
  
Intellectual Property 
 
 
7. Ensure all investigators and both partners retain their proprietary and intellectual property rights throughout and after the 
partnership. 
 
Data Sharing, Access 8. Ensure that data sharing arrangements are explicit and that all rights to access data are fairly negotiated at the outset of 
the partnership. 
  
Effective Governance 9. Establish parameters for what type of projects will and will not be funded (e.g. add-on projects, training, pilot studies). 
 10. Create ways to protect each party from an unexpected end to the partnership. 
 11. Assess formally the efficiency, effectiveness, and achievements of the partnership on an annual basis. 
 12. Ensure that clear, comprehensive, and efficient procedures exist for all governance entities of the partnership and are 
known to all investigators. 
  
Protection of Human 
Subjects 
13. Ensure that all investigators, staff and other participants in the partnership have adequate training in the responsible 
conduct of research and related ethical issues. 
14. Ensure that all projects in the partnership aim to satisfy the highest ethical standards. 
  
Publication 15. Ensure the right of all researchers associated with the partnership to publish. 
 16. Disseminate all research results at the conclusion of collaborative studies in a timely fashion. 
 17. Ensure authorship follows ICMJE guidelines. 
 
Social, Scientific, and 
Industrial Value 
18. Maintain competitive advantage in the specified research domains. 
19. Structure the research to maximize potential benefit for communities and society. 
 20. Structure the partnership to have the best chance of benefiting both partners and harming neither. 
  
Transparency 21. Widely publicize the partnership agreement and collaborative opportunities to the public and employees. 
 22. Establish procedures for frequent and effective communication between partners. 
 23. Ensure both partners are aware of other partnerships each may be involved in. 
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APPENDIX 2 
 
 
 
Annotated Bibliography 
Academic-Industry Partnerships 
(Prepared by:  Josh Rager, Avril Rua Pitt, December 2013) 
Executive Summary 
Academic-Industry partnerships have been on the rise in the last couple of decades. These 
relationships have been said to have two major benefits: increases patient access to medical 
advances, and accelerates medical innovation. (Johns et al., 2003).  Despite these benefits, these 
relationships have raised several ethical, legal and policy issues spanning from intellectual 
property, to restrictions and disclosures of conflicts of interest and publication of results. The 
overarching view held by authors is that there is a need to protect investigators and academic 
institutions from undue influence from industry sponsors that may arise from the unique position 
created by divergent interests. The literature suggests that a lot still remains to be done in order 
to protect the integrity of research, and promote the conduct of research between academia and 
industry. 
Academic Freedom 
Carpenter Jr, W. T., Koenig, J. I., Bilbe, G., & Bischoff, S. (2004). At Issue: A Model for 
Academic/Industry Collaboration. Schizophrenia bulletin, 30(4), 997.  
Carpenter et al describe a collaboration between the Maryland Psychiatric Research Center at the 
University of Maryland, Baltimore and Novartis Pharma AG. The authors outline the main 
concerns of each party preceding the agreement and discuss the nature and content of the 
collaboration’s contract as well the anticipated benefits for each party. Additionally, the authors 
describe the function and structure the collaboration in practice as well as issues that arose and 
how these were resolved. In the postscript, the authors reflect on the early termination of the 
collaboration. 
Vitiello, B., Heiligenstein, J. H., Riddle, M. A., Greenhill, L. L., & Fegert, J. M. (2004). The 
interface between publicly funded and industry-funded research in pediatric 
psychopharmacology: opportunities for integration and collaboration. Biological 
Psychiatry, 56(1), 3-9. doi: http://dx.doi.org/10.1016/j.biopsych.2004.03.011 
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The authors of this paper stress the importance of investigator-initiated grants in industry-funded 
research and discuss some of the limitations involved in industry sponsorships including the need 
for unfettered access to databases and issues and biases arising in the publication of collaborative 
findings. 
Conflict of Interest 
Bekelman, J. E., Li, Y., & Gross, C. P. (2003). Scope and impact of financial conflicts of interest 
in biomedical research: a systematic review. JAMA: the journal of the American Medical 
Association, 289(4), 454-465. doi: 10.1001/jama.289.4.454 
Bekelman et al reviewed quantitative studies on the extent, impact and management of financial 
conflicts of interest, concluding that such financial relationships are pervasive and problematic. 
Areas addressed include the effect of industry sponsorship on the study conclusion, design, and 
quality and investigator behavior. Studies on the management of financial COIs, noting that this 
is an area that is largely discretionary.  
Boyd, E. A., & Bero, L. A. (2000). Assessing faculty financial relationships with 
industry. JAMA: the journal of the American Medical Association, 284(17), 2209-2214. 
doi: 10.1001/jama.284.17.2209 
This case study of the University of California, San Francisco (UCSF) disclosure forms and 
official documents from the Office of Research Administration sought to analyze the extent of 
personal financial relationships with sponsors, their nature and efforts made to address 
disclosures and perceived conflicts of interest. Discussed in the article are the characteristics of 
positive financial disclosures, institutional responses and management strategies. 
Kuszler, P. C. (2001). Curing conflicts of interest in clinical research: impossible dreams and 
harsh realities. In Widener L. Symp. J. (Vol. 8, p. 115). 
This in-depth article discusses different sources of funding of clinical research (federal, private 
sponsor, third party payer, patient out-of pocket).; financial and non-financial conflicts of 
interest; and current methods of addressing financial conflict of interest (laws and regulations, 
institutional policies – disclosure v. prohibition). Ways of redressing conflicts of interest are then 
discussed. 
Lo, B., Wolf, L. E., & Berkeley, A. (2000). Conflict-of-Interest Policies for Investigators in 
Clinical Trials. New England Journal of Medicine, 343(22), 1616-1620. 
doi:10.1056/NEJM200011303432206 
After analyzing conflict of interest policies in 10 US medical schools that receive the largest 
amount of NIH funding, this article concludes that these policies vary greatly from institution to 
institution. These policies were also weaker than other industry-sponsored clinical trials. The 
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authors conclude that there should be higher standards for university based clinical trials than 
commercial organizations. 
Martin, J. B., & Kasper, D. L. (2000). In Whose Best Interest? Breaching the Academic–
Industrial Wall. New England Journal of Medicine, 343(22), 1646-1649. 
doi:10.1056/NEJM200011303432213 
In this article, the authors note an increase in industry funded research conducted by academic 
institutions over the last couple of decades, which has led to a breach in the wall between the 
academic and industrial worlds. After analyzing the change in nature between academic-industry 
partnerships and the disadvantages of breaching this academic wall, the paper concludes that the 
criteria for conflict of interest applied in the public sector are appropriate for the academic sector 
as well. Investigators should be free from any influence by the industry sponsor. In cases of 
patient-oriented research, the authors suggest a minimal financial relationship for an investigator 
to research on a product that may be commercialized. 
Taylor, P. L. (2013). Innovation Incentives or Corrupt Conflicts of Interest? Moving Beyond 
Jekyll and Hyde in Regulating Biomedical Academic-Industry Relationships. Yale J. 
Health Pol'y L. & Ethics, 13, 135-198. 
Taylor assesses the present COI regulatory framework for academic-industry collaborations and 
critiques its lack of scrutiny from a number of legal perspectives. Suggesting reform, Taylor 
offers a way to rectify the defects, proposes collecting data on COI regulation to better inform 
choices on forms of collaboration, offers a set of interim rules until such collection can be 
performed, and recommends the creation of “how-to” models for collaborations and anticipating 
COIs. 
Data Sharing, Access, and Intellectual Property 
Blumenthal, D., Causino, N., Campbell, E., & Louis, K. S. (1996). Relationships between 
Academic Institutions and Industry in the Life Sciences — An Industry Survey. New 
England Journal of Medicine, 334(6), 368-374. doi:10.1056/NEJM199602083340606 
Blumenthal et al considered the characteristics of these relationships between academic 
institutions and industry, the benefits realized by companies, the difficulties of collaboration 
arising from various sectors including internal policies and intellectual property, and withholding 
of data. The paper discusses both the benefits and challenges of such relationships. (Note: This is 
a 1996 article.) 
Melese, T., Lin, S. M., Chang, J. L., & Cohen, N. H. (2009). Open innovation networks between 
academia and industry: an imperative for breakthrough therapies. Nature Medicine, 
15(5), 502-507.  
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Melese et al describe the various models of industry-academia collaborations and suggest four 
steps for future collaborations to actualize the potential outcomes of such partnerships. The 
authors suggest that each party should weigh the value of their assets with those of their potential 
partner and concurrently assess these values with the value in the potential, collaborative 
outcome. The authors also suggest that industry-academia collaborations should be managed like 
an investment portfolio, adopt a new attitude about sharing information, and seek to create new 
models for collaborative innovation. 
Moses, H., Perumpanani, A., & Nicholson, J. (2002). Collaborating with industry: choices for 
Australian medicine and universities. Medical Journal of Australia, 176(11), 543-546. 
This article focuses on ways of enhancing Australia’s collaboration between industry, Australian 
medicine and universities. The growth of collaboration in the US is discussed. The authors 
categorize conflicts into 6: conflict of commitment, conflict of interest, breach of trust, 
distraction from basic discovery, compromised academic independence and different mandates. 
The Australian perspective is then offered addressing legislative obstacles, sources of funding 
and scale, noting that some Australian inventions migrate to the US which has more funding 
opportunities, larger markets and stronger legislative frameworks. 
Jones, R., Wilkinson, D., Lopez, O., Cummings, J., Waldemar, G., Zhang, R., . . . Gauthier, S. 
(2011). Collaborative research between academia and industry using a large clinical trial 
database: a case study in Alzheimer's disease. Trials, 12(1), 233.  
Jones et al describe a collaborative effort between Pfizer and a group of academic researchers to 
investigate novel aspects and treatments of Alzheimer’s disease using Pfizer’s pre-existing 
clinical databases. The authors detail how the academic team was assembled, how the specific 
investigations were agreed upon, and how the projects and collaboration were managed. 
Additionally, the authors report the successes of the collaboration as evidenced in published 
articles and advocate the scientific value of data mining. 
See also: 
Mello, M. M., Clarridge, B. R., & Studdert, D. M. (2005). Academic Medical Centers' Standards 
for Clinical-Trial Agreements with Industry. New England Journal of Medicine, 352(21), 
2202-2210. doi:10.1056/NEJMsa044115 
Effective Governance 
Mello, M. M., Clarridge, B. R., & Studdert, D. M. (2005). Academic Medical Centers' Standards 
for Clinical-Trial Agreements with Industry. New England Journal of Medicine, 352(21), 
2202-2210. doi:10.1056/NEJMsa044115 
This article studied institutional standards for restricting investigator control over clinical-trials 
agreements in 107 institutions, revealing a great degree of variance in institutional procedures. 
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The paper analyzes acceptability of restrictive contractual provisions, tensions in negations and 
disputes with industry sponsors, and tools and practices used to facilitate negotiations with 
industry  sponsors. Several strategies are proposed, among them the need for information sharing 
among institutions with the aim of building appropriate standards. 
Schulman, K. A., Seils, D. M., Timbie, J. W., Sugarman, J., Dame, L. A., Weinfurt, K. P., . . . 
Califf, R. M. (2002). A National Survey of Provisions in Clinical-Trial Agreements 
between Medical Schools and Industry Sponsors. New England Journal of Medicine, 
347(17), 1335-1341. doi:10.1056/NEJMsa020349 
This survey on the content of academic-industry clinical trial agreements contains provides 
scores for site agreements and coordinating center agreements between medical centers and 
industry sponsors. The survey revealed that some academic institutions do not adhere to the 
International Committee of Medical Journal Editors’ (ICMJE) Uniform Requirements for 
Manuscripts submitted to Biomedical journals. 
The Ad Hoc Committee on Industrial Partnership Review. (2003). MIT’s Industrial Partnerships. 
Internal Report. Massachusetts Institute of Technology. 
http://web.mit.edu/chancellor/IndlPartnershipsRpt.pdf 
This is an internal report of an ad hoc committee at MIT created to review the university’s 
numerous partnerships with industry. Included in this report is a summary and history of MIT’s 
partnerships as well as lists and discussions of the benefits and risks of MIT’s industry 
collaborations. The committee’s report also includes a description of best practices in industry-
academia collaborations and recommendations for future partnerships.  
Joint Project of the National Council of University Research Administrators and the Industrial 
Research Institute. (2006). Guiding Principles for University-Industry Endeavors: 
National Council of University Research Administrators. 
Joint Project of the National Council of University Research Administrators and the Industrial 
Research Institute. (2006). Living Studies in University-Industry Negotiations: 
Applications of the Guiding Principles for University-Industry Endeavors. B. M. K. 
James J. Casey Jr., National Council of University Research Administrators. 
University-Industry Demonstration Partnership Researcher Guidebook Worling Group. (2012). 
Researcher Guidebook: A Guide for Successful Institutional-Industrial Collaborations. 
Atlanta, Georgia Tech Research Corporation. 
University-Industry Demonstration Partnership Working Group. (2012). Partnership Continuum: 
Understanding & Developing the Pathways for Beneficial University-Industry 
Engagement. Atlanta, Georgia Tech Research Corporation. 
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University-Industry Demonstration Partnership. (2012). Contract Accords 1-10: For University 
Industry Sponsored Agreements. Atlanta, Georgia Tech Research Corporation. 
University-Industry Demonstration Partnership. (2013). Contract Accords 11-15: For University 
Industry Agreements. Atlanta, Georgia Tech Research Corporation. 
These publications are guidebooks created and compiled by the University-Industry 
Demonstration Partnership. Included in these documents are guiding principles for university-
industry collaborations, case studies, materials for both academic and industrial researchers new 
to these collaborations, and methods for constructing fair and comprehensive contracts. All of 
these publications can be found at http://sites.nationalacademies.org/PGA/uidp/PGA_055253 
See also: 
Carpenter Jr, W. T., Koenig, J. I., Bilbe, G., & Bischoff, S. (2004). At Issue: A Model for 
Academic/Industry Collaboration. Schizophrenia bulletin, 30(4), 997.  
Melese, T., Lin, S. M., Chang, J. L., & Cohen, N. H. (2009). Open innovation networks between 
academia and industry: an imperative for breakthrough therapies. Nature Medicine, 
15(5), 502-507.  
Protection of Human Subjects 
 
Klitzman, R. (2013). How IRB Leaders View and Approach Challenges Raised by Industry-
Funded Research. IRB: Ethics & Human Research, 35(3), 9-17. 
Klitzman reviews responses by IRB chairs, administrators and members on challenges they face 
in industry-funded research. It also reviews IRB decisions and responses to assessing and 
weighing problematic studies with perceived low social benefit. Issues mentioned include 
uncertainty as to the suitability of an institution in conducting a study, studies that diminish the 
scientific utility of research, and whether some industry funded studies are even research. 
Publication 
Bodenheimer, T. (2000). Uneasy Alliance — Clinical Investigators and the Pharmaceutical 
Industry. New England Journal of Medicine, 342(20), 1539-1544. 
doi:10.1056/NEJM200005183422024 
After a brief background on the clinical drug trial system and the tensions and shift from 
academic medical centers to contract-research organizations and site-management organizations, 
the article discusses the industry-investigator relationship with regard to trial design, data 
analysis, publication of results and control of publication, and authorship. The authors conclude 
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that academic-industry drug trials have the potential of balancing the commercial interest of 
industry and scientific goals of investigators. 
Wager, E., Field, E. A., & Grossman, L. (2003). Good publication practice for pharmaceutical 
companies. Current Medical Research and Opinion, 19(3), 149-154. 
doi:10.1185/030079903125001767 
The authors propose Guidelines on Good Publication Practice (GPP) aimed at ensuring that 
industry sponsored clinical trials by pharmaceutical companies are published ethically and 
responsibly. The article describes how these guidelines came about, the need for more 
guidelines, issues addressed by the GPP, and how they should be applied. The guidelines apply 
to phase II, III and IV trials, and exclude independently published studies. 
See also: 
Carpenter Jr, W. T., Koenig, J. I., Bilbe, G., & Bischoff, S. (2004). At Issue: A Model for 
Academic/Industry Collaboration. Schizophrenia bulletin, 30(4), 997.  
 Blumenthal, D., Causino, N., Campbell, E., & Louis, K. S. (1996). Relationships between 
Academic Institutions and Industry in the Life Sciences — An Industry Survey. New 
England Journal of Medicine, 334(6), 368-374. doi:10.1056/NEJM199602083340606 
Schulman, K. A., Seils, D. M., Timbie, J. W., Sugarman, J., Dame, L. A., Weinfurt, K. P., . . . 
Califf, R. M. (2002). A National Survey of Provisions in Clinical-Trial Agreements 
between Medical Schools and Industry Sponsors. New England Journal of Medicine, 
347(17), 1335-1341. doi:10.1056/NEJMsa020349 
Vitiello, B., Heiligenstein, J. H., Riddle, M. A., Greenhill, L. L., & Fegert, J. M. (2004). The 
interface between publicly funded and industry-funded research in pediatric 
psychopharmacology: opportunities for integration and collaboration. Biological 
Psychiatry, 56(1), 3-9. doi: http://dx.doi.org/10.1016/j.biopsych.2004.03.011 
Social, Scientific, and Industrial Value 
Clackson, T. (2006). Translational Research in Academia and Industry. Experimental Biology 
and Medicine, 231(11), 1685-1689. 
This article considers two case studies: Epidermal Growth Receptor Biomarkers, and Chemical 
Dimerization. Factors necessary for successful academic-industry relationships are considered. 
Johns, M. M., Barnes, M., & Florencio, P. S. (2003). Restoring balance to industry-academia 
relationships in an era of institutional financial conflicts of interest. JAMA: the journal of 
the American Medical Association, 289(6), 741-746.doi: 10.1001/jama.289.6.741 
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Johns et al concludes that industry-academic partnerships should not be allowed if they only 
serve the pecuniary interest of the holder without directly or materially furthering scientific 
advancements referred to as the justification test. The article discusses the nature and operation 
of financial conflicts of interest and strategies for dealing with them. It also proposes a 
justification test in order to reduce the appearance and potential of bias. 
See also: 
Blumenthal, D., Causino, N., Campbell, E., & Louis, K. S. (1996). Relationships between 
Academic Institutions and Industry in the Life Sciences — An Industry Survey. New 
England Journal of Medicine, 334(6), 368-374. doi:10.1056/NEJM199602083340606 
Carpenter Jr, W. T., Koenig, J. I., Bilbe, G., & Bischoff, S. (2004). At Issue: A Model for 
Academic/Industry Collaboration. Schizophrenia bulletin, 30(4), 997.  
Transparency 
See:  
Carpenter Jr, W. T., Koenig, J. I., Bilbe, G., & Bischoff, S. (2004). At Issue: A Model for 
Academic/Industry Collaboration. Schizophrenia bulletin, 30(4), 997.  
 
55 | P a g e  
 
IUCB Report on Regenstrief-Merck Partnership 
APPENDIX 3 
Introduction:  [To be read out loud].  
Thank you all for agreeing to meet with us today. Before we begin, we’d like preface our 
discussion with a reminder of the background to this review and outline what we’ll be doing 
today. 
 In 2013, the IU Center for Bioethics was invited by Dr. William Tierney, President/CEO of the 
Regenstrief Institute to formally evaluate the Regenstrief Institute’s role within the current 
Regenstrief-Merck partnership with the expectation that it be done on an annual basis, and the 
results be published in the peer reviewed literature. The evaluation is being done under contract 
to the IU Center for Bioethics. 
The particular focus of the evaluation is Regenstrief’s role in the partnership with the main goal 
being to provide substantive actionable recommendations to Regenstrief. In so doing, it is 
intended that this evaluation will aid in the ongoing Regenstrief-Merck partnership and that it 
will also become an exemplary model for other public-private collaborations undertaken by 
Regenstrief.  
Part of the evaluation involves understanding and assessing the perspectives of key leaders 
involved in managing the Regenstrief-Merck Partnership. That is the focus of today’s session. 
You were selected as a participant because you are a member of the Regenstrief-Merck Steering 
and/or the Operations Committees. Today you will be asked to answer questions about the 
Regenstrief-Merck partnership.  
To facilitate this discussion we will refer to a set of ethical principles and an accompanying list 
of benchmarks for model partnerships. They have been developed by the IU Center for 
Bioethics specifically for this project.  We’ll be asking you about how these benchmarks and 
principles  are reflected in the Merck-Regenstrief partnership. We expect that they will stimulate 
discussion. 
The session should last approximately 90 minutes to 2 hours. In addition to note-taking,  we will 
be recording and transcribing the discussion  for analysis. We will not identify individuals by 
name, and all audio recordings and transcriptions will be destroyed once we have completed the 
analysis.  However, we do intend to publish a scholarly article based on the results of the overall 
evaluation and may include quoted material from this focus group in the publication. The IU IRB 
determined this project to be exempt from review. 
Your participation in this study is completely voluntary, and if for any reason you wish to 
discontinue your participation today, you are welcome to leave. If any issues or concerns should 
arise after your participation in this study, you’re welcome to raise them now or to follow up 
with me afterwards. 
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Are we ready to begin? 
*** 
Lead-in question: The first principle is academic freedom which concerns researchers’ ability 
to pursue their own, individual academic interests as they see fit.  Do you feel this is important?  
Have you confronted any issues related to this?  Was this something that you anticipated or 
thought about at the outset of partnership? What have you all done to promote and ensure 
academic freedom?  
Probe on: 
• Promoting investigator-initiated science and continued ability to attract federal research 
support 
• Permitting investigators to initiate or continue partnerships with other qualified persons, 
groups or entities 
• Ensuring all investigators have equal opportunity to submit for funding 
• Not obligating faculty to work outside their own self-defined scientific area 
• Others? 
Follow-up: How well do you think the partnership has done promoting this? Have any issues 
arisen regarding this principle either within this group or among the investigators? 
Lead-in question: The next principle is Conflict of Interest that is, managing the competing or 
potentially competing commitments and/or financial conflicts of involved parties and persons.  
Has this been a challenging issue for you?  What measures have you all taken to eliminate, 
manage or control such potential (or actual) conflicts?  
Probe on: 
• Protecting students, fellows, and post-docs involved from exploitation 
• Ensuring effective mechanisms exist to eliminate, control, or manage COIs. 
• Others? 
Follow-up: What mechanisms are in place? And, if any issues have arisen, how have you all 
dealt with them? 
Lead-in question: The third principle concerns protecting the intellectual property and 
proprietary rights of each partner throughout and after the partnership, including fair data 
sharing and data access agreements. These issues were addressed in your contract with Merck. 
What have you all done to promote and ensure this principle? 4 
4 At the time of the focus group, we combined the principles “Data Sharing, Access” and “Intellectual Property,” but 
subsequently split these into two principles giving us the present total of 9 principles. The investigator survey and 
final analysis were all conducted under the 9 principle format represented throughout this report.  
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Probe on: 
• Ensuring all investigators and both partners retain their proprietary and intellectual 
property rights throughout and after the partnership.  
• Ensuring that data sharing arrangements are explicit and that all rights to access data are 
fairly negotiated at the outset of the partnership. 
• Others? 
Follow-up: How well do you think you’ve done in promoting and ensuring this principle? Have 
any issues arisen concerning this topic (if so, how were they resolved)? 
Lead-in question: The fourth principle concerns how the partnership is managed and led 
including but not limited to legal issues, administrative duties and obligations, priority setting 
and managing conflicts. All of which may be captured under the term governance. What do you 
think are some essential features for effectively managing a partnership like this in a way that is 
fair and enabling toward the investigators? If asked to list important parts of effective 
governance, most people would list fairness, cooperation, and communication.  Do those sound 
right to you?  Are there other goals you would suggest?  How well do you think you’ve done in 
accomplishing these?   
Probe on: 
• Establishing parameters for what type of projects will and will not be funded (e.g. add-on 
projects, training, pilot studies). 
• Creating ways to protect each party from an unexpected end to the partnership. 
• Assessing efficiency, effectiveness, and achievements of the partnership on an annual 
basis. 
• Ensuring that clear and comprehensive procedures exist for all governance committees 
and are known to all investigators. 
• How are the Areas of Interest decided? How are decisions made as to what projects will 
be funded? 
• Others? 
Follow-up: Can you give examples? 
Lead-in question: The fifth principle focuses on the requirement that the research conducted 
within the partnership should adhere to the highest ethical standards for protecting human 
subjects.  Have there been issues that have arisen for you in this area?  Were they affected at all 
by the fact that it was a partnership?  What have you all done to promote and ensure this 
principle?  
Probe on: 
• Ensuring that all investigators, staff and other participants in the partnership have 
adequate training in the responsible conduct of research and related ethical issues. 
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• Ensuring that all projects in the partnership aim to satisfy the highest ethical standards. 
• Others? 
Follow-up: How well do you think you’ve done? If any issues have arisen, how were those 
issues resolved? 
Lead-in question: The sixth principle concerns issues of authorship and how research 
findings are to be published, disseminated, or known.   Have there been issues that have arisen 
for you in this area?  Can you give some examples?   What have you all done in regards to 
ensuring good publication practices and adherence to authorship rules?  
Probe on: 
• Ensuring the right of all researchers associated with the partnership to publish. 
• Disseminating all research results at the conclusion of collaborative studies in a timely 
fashion. 
• Ensuring authorship follows ICMJE guidelines. 
• Others? 
Follow-up: How well do you think you’ve done?  
Lead-in question: The seventh principle concerns the benefits to each partner and the goals of 
each partner in the collaboration. The general idea is that the partnership should create new 
knowledge that will improve the well-being of citizens and be of significant importance to the 
academic and industrial partner.  Does that sound like an important goal to you?  Is it one that 
you have had to think about or apply so far?  Examples?  What have you all done to promote and 
ensure this principle? What are some the potential or actual benefits of collaborating with Merck 
for both you, the company, and society? Are there any potential or real harms to collaborating 
with Merck? 
Probe on: 
• Maintaining competitive advantage in the specified research domains. 
• Structuring the research to maximize potential benefit for communities and society. 
• Structuring the partnership to have the best chance of benefiting both partners and 
harming neither. 
• Others? 
Follow-up: How well do you think you’ve done in promoting this principle? Have any issues 
concerning this topic arisen? 
Lead-in question: The eighth principle concerns how well the collaboration (its function and 
agreement) is known by and visible to relevant parties and the public.  Do you feel the 
collaboration is well enough known in this way?  Has this been a concern of yours?  What have 
you all done to increase and ensure transparency?  
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Probe on: 
• Widely publicize the partnership agreement and collaborative opportunities to the public 
and employees. 
• Establish procedures for frequent and effective communication between partners. 
• Ensure both partners are aware of other partnerships each may be involved in. 
• Others? 
Follow-up: How well do you think you’ve done? Have there been any surprising issues that have 
arisen on this topic? 
Closing Remarks: Thank you for your time. Please remember that if there are any additional 
concerns or comments after this group is adjourned, feel free to contact me or any members of 
our team.  Once we have gathered and analyzed our data for this review, we look forward to 
reporting back to you all. 
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APPENDIX 4 
Academic Freedom 
“It's safe to say that we were very keen on protecting it, which means we must have worried that 
it would be at risk, you know?...what I thought at the time was, yeah, we want to be sure that 
we're not either a shill for or just a guardian of stuff that's for purely industry purposes so it was 
on the radar.” (6) 
“but I think the greatest risk here is that we were going to be taking an investigator who might 
better spend his time focusing on something else more on the line of his or her previous research.  
Because that person needed research funding support and are unable to get it themself, we're 
gonna buy that person to work on our stuff and unfocus his research career.” (6) 
“ this is one of the early discussions we had is that we need to find ways that their research 
interest and our research interest overlap so that the investigators on both sides are doing what, 
as a mutual interest, otherwise the partnership is not gonna make it.  And that, I think, is a way of 
kind of coll - academic freedom in a collaborative way.  So, we each have the freedom to 
brainstorm and pick things that turn us on and then propose them and then we can decide to fund 
them or not fund them depending on relevance and interest and rigor and all those other kind of 
things, but at the end of the day, we did give people the - we didn't just say, OK, Merck wants 
this project done.” 6 
“we talked about that in early meetings as a very general term, and John came up with this notion 
and we'll look for things that co-PIs on both sides and throw things - and each group will throw 
things on the table.” 7 
 “I would say that I have come to - since we're worrying more about academic boredom than 
academic freedom, you know, that you're just gonna be doing something… That's the statement 
because that's the reality, is that you're just doing something which is like, yeah, we can do it.  
We can run that analysis.  We can look at this.  We can look at that and, in part, which is why 
Jennifer put together this exploratory studies project, which was sort of a mini - kind of people 
want to take a quick look at something.  It doesn't require a lot of research or support.  We found 
mechanisms to do sort of run of the mill things, but that real issue about like is it just gonna be a 
also ran tenth time somebody's looked at this issue.  So, I think around academic freedom, that's 
sort of exactly what Bill is saying.  Is it gonna careen somebody's career by just doing mediocre 
science?” 7 
“So, the exploratory studies project, we started it last summer, so about a year and a half into the 
project, into the whole collaboration, and the point was to be able to do these little research 
questions that aren't full projects that don't need a lead on both sides and the full rigor of what we 
do for regular projects, but can just be sort of either they don't have a Regenstrief lead or they 
don't really need all of that planning so they can just be kind of quick one-offs, and one example 
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of how this has been useful recently is that we had a group at Merck who was looking at ,I think 
it was for chronic kidney disease, one of those drugs.  So, we had a phone call and we had 
someone from IU who's like an expert in this call in and so the call didn't go very well, and they 
didn't really come together.  Afterwards, he emailed us and said, you know, these aren't 
interesting questions.  This has been done.  Basically for business reasons, I'm not interesting in 
spending my time on this.  So, he felt very free to do that.  There was no coercion.  There was no 
- he didn't suggest somebody else because he knew no faculty member would want to spend time 
on this, but we still have a mechanism just with our data core and our project management 
structure to do those sorts of things without impeding on anyone else's time.” 7 
“The proposal process really highlighted this…if an idea came from Merck and there was no 
interest here, then there was no interest here and same with ours….Jennifer would do is solicit 
ideas from IU people and then her counterpart would solicit ideas from Merck and then we'd put 
it all together and socialize them.” 8 
“I realized that I didn't really understand what Merck did.  What are the diseases that they focus 
on?  I know these companies have hot diseases within them where all the drug development is 
focusing on, and they put hundreds of millions of dollars into stuff, and I had no idea.  I go, 
shouldn't I know that?  So, I asked the question, and it was amazing.  They kinda didn't know 
that cause these were all working in epidemiology and in global health.  Whatever it was, they 
had snippets, like somebody knew something.  So they threw out the things they knew about, but 
nobody had kind of global knowledge about it.” 8 
“But the point is that to serve the academic freedom, we took big A academic.  In other words, 
we a broker and one of Regenstrief's notions that we're supposed to broker research and look 
beyond our walls.  So, it may not have served our investigators, but it serves our customers, 
which is the university.  We're here to support the university.” 9 
“They have spent what is probably hundreds of hours to get thing finalized because of the 
incredibly ridiculous, odorous, but that's the right way to do regulation.  So, just in general, 
there's a huge amount of sensitivity to ensuring that there's not the perception of a - so just to 
kind of lay that out.” 10 
“, if there is not a compatriot found, then it just dies.  So, there shouldn't be any circumstance 
where someone is coerced into studying something that is outside of their own self-defined 
scientific area.  Everybody should - there's no pressure to do that.” 10 
“.  A lot of the Merck scientists, and I think I'm the only person who has led, who has PI'd these 
projects, are better than us.  They're better.  They're scientifically better at certain things than we 
are.  I'll just be honest with you.  They provide suggestions and insights that are more rigorous, 
of higher quality, higher scrutiny, better defined than what we came up with….  It was nothing in 
their interest, it was just methodology, random crap, but they've got scientists who are very good, 
in some cases better than we are, and I think that we have to have that recognition, like academic 
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freedom to be like, you know, you are actually getting advise from somebody who knows maybe 
more than you do about some things.  To me, that's an interesting part of the story.” 10 
“The investigators here don't always recognize that in their Merck counterparts because they will 
come back with something, and they'll be - they'll say, oh, just - they're trying too hard to tightly 
control it, but she was right. You can't control that.  You can't compare that as a control group 
because she's right.  They don't match or whatever.  It usually comes up with methodology in a 
study design and not even like you were saying, but it's interesting to listen to both sides of that.” 
11 
“there is a bias towards if you're a really smart investigator, you stay in academia.  If you want to 
essentially be told what to do and run some other studies, you go to industry and those who have 
actually worked with people have realized there's some really smart people out there. We do not 
have the corner on the market of intelligence, and so I don't think any of us, it was a revelation 
when people are saying, well, of course, but I think there is a bias amongst some of our 
colleagues, both in the institute and outside the institute that we're kind of smarter than they are 
and part of our kind of grooming people to be part of this is to level the playing ground on both 
sides.  And I must say that on the financial side of stuff, on the resources side of stuff, it's the 
opposite.  That Merck thinks they're rich and we're poor... He says we're putting money on the 
table, we make the rules, and I said money is the cheapest thing on the table right now.  The 
toughest thing on the table is our intellectual capacity.  That's - you know, so it was not a matter 
that we're subjugated to you.  You bring something and we're bringing something to the table.  I 
argue that money's a lot cheaper than a kind, and so we leveled the playing field by that.  So, 
there were biases on both sides based on assumptions about the other guy, neither one of which 
was valid.” 11 
EMM suggestion of academic curiosity 
“I see a lot more curiosity.  Maybe it's just my interest biases, but curiosity in the developments 
side.  The folks who are coming from the IT side who say let's build out a new thing for an 
[INAUDIBLE].  Those guys are much more like let's experiment and explore new ground.  With 
the methodology folks, we get some of that same kind of thing where I think there's sort of an 
academic curiosity.  I think with a straight analytics projects, which is probably for lack of a 
better word, sort of the bread and butter, look at adherence in patients, less of a curiosity driven 
thing to me, but that's just my –“ 12 
“ So, there are - I think some of the curiosity is on the methods and not on the focus, and that's 
where you sometimes get.  I want to do this in melanoma.  I don't want to do this.  Well, fine I 
don't care about melanoma, but I want to do that.  So, that's the marriage, and if it weren't that 
way, how are you going to find people, enough people who want to do melanoma to put a project 
together.  Its such a narrow corner.”12 
“Go get a grant” 13 
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“We - it's a little bit - it's not quite bilaterally symmetrical because, you know, I'm sure if nobody 
at Regenstrief was interested, John would knee jerk reaction might be, well, then we're not 
interested, but one of my roles is to be a matchmaker and to work the interfaces and stuff like 
that.  So, I will push it.  We'll see if there's somebody else around here that might be interested in 
that because it both make Merck happy and it makes Regenstrief important - I can tell you that, 
for example, endocrinology thinks much more highly of us now than they did before we have the 
osteoporosis center, and it's spontaneous to see how wonderful Regenstrief is.  Cause we've 
created some nice opportunities for them that weren't anticipated and really don't benefit us very 
much.  So, there's some collateral benefit for us which is tremendous and what's it cost us?  
We're bringing more money in.  We get to claim it all as part of our grant so our board says, god, 
that's a lot of money.  That's great.  You created this other center.  That's terrific and for us, it's 
just OK, we'll do that and it's been modest amount of work on our part and a huge amount of 
benefit for the university.” 13 
Conflict of Interest and Commitment 
“I can't think of any conflicts or anything that's come up in this area.”13 
“But we haven't asked, right?  We've never asked our people if they own stock, own competing 
stock.”14 
“I only just make sure they fill it out in the IRB.”14 
“The one conflict that came to my mind potentially in this area is that the bone center often 
serves and is serving as a test facility for the clinical trial for Odanacatib, which is the new 
Merck osteoporosis drug.  And I don't know how that - I don't think there's been an impact, but 
it's there.  It's the same guys.” 14 
Back and forth among participants about who fills out a COI form and who  doesn’t. 14-16 
“There have been questions from our folks about how to do the conflict of interest, you know, on 
a publication and what sort of phrasing should they use to describe this.” 16 
“But let me clear - there's an exploration of this that actually never came up until last week and 
that is that, for example, our investigators just a fraction of their salary paid.  They don't 
personally get honoraria or anything for this.  It's just buying their time to work for the institute, 
and I'm assigning the work on this.  We're actually doing it for things not Merck, too.  So, this 
isn't the only thing we're using this method for.  But, you know, I'm the president of the institute 
and the institute, if the institute succeeds, do I benefit from that?  So, if the institute is 
benefitting, is that a conflict of interest for me?  “ 16 
“the fact that I represent an organization that itself can benefit becomes an important conflict of 
interest at times, and I don't know how to factor that into this yet.” 17 
64 | P a g e  
 
IUCB Report on Regenstrief-Merck Partnership 
“Well, I think the problem is because none of us personally benefits from this.  We just get our 
salary paid.  OK?... You're losing because it's pulling your focus away from helping what 
direction of your career to go, and we're benefitting from that lack of focus.  And the other thing, 
if I'm gonna be supporting 20 percent of a whole bunch of people to be working on this from 
other things, they're now working for the institute for the institute's benefit, and I think it's gotta 
be clear that it's not necessarily for their benefit, and it has to be up front acknowledgment 
because there's, at times, gonna be a conflict of commitment.” 18 
“It's not real money, and we're attracting people away from what would be considered more 
academic lucrative things to be doing, chasing the easy money and dangling it in front of them.  I 
don't know.  I can see that argument happening.” 18 
“maybe you're taking advantage of faculty and that's sort of a conflict of interest with us in doing 
it.  I think another side that I find totally know how to reckon is relationships with other 
companies or parties who are interested in us and how our relationship with Merck affects 
that…I mean, I know you can say well, that's just a tangled web you weaved, but it could just as 
well be like maybe I shouldn't apply for this $100,000 NIH grant to study the risks associated 
with Cycliftin because that's Merck.  You know, so I think there's also stuff that actually affects 
the way I look at other relationships which is sort of a conflict of interest maybe in a way that I'm 
benefitting from or it's actually disadvantageous for me, but there's some effect.” 19 
IP, Data Sharing, Access 
“I think, from a faculty perspective, people probably feel like Regenstrief underleverages IP as 
generated here.” 19 
“Well, we've just built a hell of a lot of stuff over the last 40 years and a lot of foundational work 
and don't really have the IP to show for it.” 20 
“The relationship we have with Merck is an interesting one insofar as the contract says that they 
have the right of first refusal for anything developed under this agreement.  The NLP stuff might 
be a good example of that.  That they have the right of first refusal to take it and market it and 
actually had trouble signing that aspect of the contract until we had our agreement signed with 
IU.  Because for 25 years, our investigators have been signing a form with IU saying f\IU owns 
all the intellectual property.  They've been signing a form for Regenstrief, saying Regestrief 
owns all the intellectual property, and we finally resolved it so that depending on who funded the 
project, if a property belongs to either IU or Regenstrief… we have the ability to market stuff, 
and we're going to be doing more of it, but the issue is one that has not been discussed a lot until 
the past year among the faculty, and now it's being discussed a whole lot among the faculty and 
we're moving to support it.” 20-21 
“In the contract, I think it was definitely much more - certainly, the Merck side said a, we want 
things to be - we want - want we develop it together that we can assign the IP and exactly as Bill 
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referenced, the biggest issue was that we would not be able to cleanly assign IP because IU had 
official ownership stake.  The whole thing almost cratered until I remembered Thursday 
afternoon, one week I was in clinic and I had to call Mr. Betley and say, as chairman of the 
foundation and the board, etc., the only thing that's left that can save this is you simply saying 
you will personally make assurances that - like if Regen - if IU tries to come in and swoop it, and 
that's what it took.  Then, eventually, we got a real contract signed.  So, in practice, it was 
Regenstrief.  I mean, it was Merck.  In reality, they've been very big on the open source sort of 
agenda that we have here because most of our development from an IP standpoint has been IT 
and they are very interested in building things that get other people to use it to be able to produce 
data that can be leveraged for other purposes.  So, supporting open MRS is a very big interest of 
theirs.  They haven't seen like, "oh there's huge money in them thar hills" because we built this.  
Rather, they see it in getting it out more broadly and making Merck look great and all of that as 
having more value.” 21 
“We haven't had any IP generated in the sense that we've built stuff, but we haven't had any 
patents submitted for our IP.  We haven't had any things that have executed on that yet.  I think 
that will be coming this year. “ 22 
“We haven't fought over any IP.” 22 
“.  They explicitly said it obviously reflects well to be working with an independent organization 
like Regenstrief Institute and of course, that's a tip of the hat to the public relations benefit of 
working with an organization that's respected and that is known for its openness.  So, that's one 
benefit.  Two is, we've taught them and they have taught us a lot about partnering.  We are - I 
mean, the process that we've built.  Jennifer, primarily, and these guys over the past couple years 
has proven to be extremely potent and reusable, and they now extend it to nine other 
partnerships, and so we were sort of this prototype partnership which they learned from, and I 
think that they have sort of held us up also as an example of just an effective, from almost a 
social level, that –“ 22 
“Who wants to argue that's a certain amount of intellectual property.  Although it can't be 
patented, it certainly can be modeled.  It can be –“22 
“Well, we're writing a paper on it so I guess we're shooting it out about the structure of the 
partnership in terms of that.” 23 
“I think our proposal process is really good…His name is Arnaud and working very closely with 
him has been very important just to communicate.  I never really speak with the investigators on 
the Merck side, but he does and so if I have a question, I go through him.  So, just having sort of 
the two - I'm the contact for our group, and he's the contact for their group, it's been really useful 
in keeping things smooth and making sure that we don't have a lot of cross communication.” 23 
Benefits/Value 
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“model by the way we internally structure the finances for this was unique.  It took me nine 
months to get IU to agree to it, starting at the level of the person that we would be setting up 
accounts at IU all the way up through the university president and getting a commitment that the 
institute could actually buy time of faculty… When you're doing a $13 million project, all the 
sudden, it gets people's attention and all of the paranoia about you're just getting around trying to 
pay indirect costs and stuff like that.  And so, so this got us a chance - if the institute was gonna 
actually change its business model to a certain degree.  We're still gonna support our 
investigators, but actually become something the institute itself does, then you're not gonna be 
able to set that up unless you just do it.  You can't set it up as a thought process… actually do 
work as an institute rather than just this notion of supporting a bunch of independent agents, then 
I've gotta work through the processes.  We've got to get approvals, we've got to send money 
through.  It's gotta actually work, and people gotta get rid of their paranoia and it actually served 
that purpose reasonably well, but not without its heartaches.  It took IU despite the fact that they 
dictated the terms and we followed them to the letter, it took them 18 months to sign the 
agreement and even then, they only signed it because the departments are screaming that we had 
more than $1 million in the transfer account and they couldn't download it without a signed 
agreement.  And they still don't feel comfortable with it.  So, it's - and I'm not exactly sure why.  
It's just different, and IU is allergic to different.” 24 
“The benefit to me was we've got a chance to actually do it.  A huge benefit to the institute cause 
we're now getting ready to roll it out maybe institute-wide. “ 24 
“So, I would say - you talk about the financial structure, but the logistical structure, the 
operational structure of executing projects has also evolved which has been extremely effective 
in terms of the cores, the biostat score, data core, NLP core, operations, just the structure.  I feel 
like it's so much easier.  Now, if we had a project coming from anybody.  Like forget Merck, just 
like somebody came along and wanted to do a project, we just stuck it into the pipeline, we 
would know exactly how to channel it, manage it, get it done, wrap it up, turn it back.  I mean, 
we have a system.  We didn't have a system so –“ 24  
“the process to propose and review projects works extremely well and if you could sit in the 
session with us when the steering committee meets, it's a mini study session.  It's kind of a low 
key study session.  We go over methods, we go over values.” 24 
“If Merck comes by and says how much money do they put into it, we just go down until it adds 
up and we fund everything above the line.  I mean, it works extremely well and everybody… So, 
everybody is very comfortable with that.  It's fair, it's effective, it's not time consuming.  They 
deal - the projects are these little concept proposals.  They're called -… Charters.  Doesn't make 
any sense, but these little concept papers, three or four page paper that's got an estimated budget, 
and we end up - it ends up being really a highly effective way that if we didn't have something 
like this to force us to do this, we wouldn't have discovered it, and it's now, I think, an executable 
model in a lot of different potential partnerships.“ 25 
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“and I think the funding relationship is such that we can, if we have a great idea or we have 
something that we're cooking, we could reach out to an organization that's interested in all kinds 
of stuff and say this wasn't part of our plan, but what do you guys think about, you know - are 
you interested in this space that we're getting into.  So, from a funding perspective, it's great… 
We're able - right now it would be very difficult for me to come up with a small idea outside of 
our innovation challenge, go to the NIH and say I need this, but with Merck, we can say we want 
to build out our hidoop cluster.  Are you interested in helping support that or something, and they 
may be or they may not.” 25 
“Well, benefits to the participants.  A couple of times, we've had projects that have been 
successful and that people have been really interested in, and the collaboration gets the 
investigators an option to submit for a second year if they want to expand the research or if the 
team's working very well together, but I can't –“ 26 
“I've had some good science come out of mine.  I know we spent a lot of time looking at - well, 
it doesn't matter about the details, but essentially, there's a bunch of people who have chronic 
kidney disease who might be getting a drug they shouldn't be getting so that was something we 
were able to ascertain.” 26 
“The efficiency says something.  I mean, if you said, well, as a member of society, we have a 
researcher here at this university that just received a five year award to investigate potential risks 
of bisphosphates in patients with renal dysfunction and in 2018 -… OK.  OK.  That's good, but if 
you said there's a group to be working and in 12 months' time they're going to come forward and 
have a planned strategy recommendation for this group to understand the incidence and their 
whole - you know, you might say, as a member of society, yeah, I'd take that latter one.” 27 
“So anybody with a DEXAscan in this area and your patient, you can look them up and find a 
result.  Until we started doing that, zero were available electronically.  So, for a population of a 
million people, we're gonna have all of their scans.  Well, that's huge.  People use those data all 
the time, and they're not available if you didn't do the scan, if you don’t have the paper result.  
So, by building infrastructure for us to do the research and making that infrastructure part of the 
system and not just part of a research project, we've benefitted the system, and that was one of 
our goals, was can we make the system better and then do research, and the system itself has to 
benefit from it.  That was a very explicit goal on the part of both Regenstrief and Merck to make 
this available.  Obviously, we're going to take advantage of it, but long after we're gone, they're 
still gonna be being captured cause we've automated that process.” 27 
“We'd be hurting if it hadn't been for the industry partnership, and its not just this fund.  There 
are other ones, but this is a huge one for us.  This is the biggest one, and it's a model for how, in 
this day and age of funding, we need to have an effective governance system so that we can take 
advantage of the fact that there is certain sectors of the life sciences industry that are looking for 
partners like us, and we'd be more than happy to serve that interest if it serves our interest at the 
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same time, and that's the key.  We just chase the dollars and survive, we can survive and be 
soulless.  So we have to make sure that we stick to our mission and keep that emblazoned on our 
walls so that we use this as a way to continue it at a time when other funding is tenuous.” 28 
“we hire investigators who have an interest in - their mission and our mission are at least co-
linear if not overlapping, and if our investigator is interested in doing something - if there's 
something our investigators aren't interested in doing something, we're not gonna do it because, 
by default, we have to have a local partner, and so as long as our investigators stay focused on 
their personal mission and it's tied to our mission, I think we're OK… but as long as it's 
answering the research question you're interested in and you were hired because you had 
interesting research questions you were interested in, I think we're OK, and we” 29 
“there's no question that they derive benefits from some of the stuff we're doing, and some of the 
stuff we're doing, we might not have done had they not proposed it, but we cert –“ 29 
“Maybe one of the suggestions from this is that in our charters, there ought to be a line as what's 
the benefit to science, what's the benefit to society?  Maybe that will be something we explicitly 
consider with each charter, and it ought to be in things that are otherwise balanced, equal.  
Maybe that ought to be the deciding factor.  This thing is actually gonna have more downstream 
benefit than another one.  And maybe just be explicit about it so that when somebody says what 
the hell good is this, we have an answer up front cause that was actually a plan from the 
beginning.  That might actually be useful and it takes almost no time.” 30 
“The first year it was us because it a long time for the Merck investigators – for it to perculate 
throughout Merck for Merck to figure out that there's something here, but once they came this 
year, it was very heartening to see that of all the things that plopped on the table, there was 
Merck that had a half and Regenstrief had the other half, and it was –“ 31 
Transparency 
“We tried to go pretty wide. So we sent it - I got help from the CTSI using their listserv” 32 
“And then anyone who is part of Regenstrief, our affiliates, our investigators.  We sent out just a 
very general email about what the collaboration is and what we are looking for, and our steering 
committee prior, the one immediately prior to this initial call, we had - I think we had five 
minutes at the end of that one to talk about well, what are you guys interested in for this year and 
ask Merck what general areas and they listed some, but they were very general and kind of all 
over the place so that wasn't all the helpful.  So, I put that in the email that said we'll accept 
proposals from anything.  So, I got a lot of responses here.  I don't remember exactly how many, 
but 30-40, maybe, people.  And at that point, all we asked for was a couple of sentences.  It 
wasn't a lot of work on the investigators' part to do that and then I put all of those in a 
spreadsheet.  We sent them to my counterpart at Merck and the steering committee members 
from Merck and said do you all have anyone on your end who would be interested in any of 
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these and then, likewise, my counterpart did the same thing on his side and sent me a spreadsheet 
that we circulated.” 32 
“I mean, it was sort of obvious that like here's stuff that's kind of about drugs and clinical stuff.  
Here's stuff that's kind of about informatics and things.  So, I think to look at it, you would 
probably so, oh, I'm guessing this is stuff that Merck cares about and stuff that Regenstrief cares 
about.” 33 
“But we certainly didn't have like a document of how we arrived at that.” 33 
“There's a difference between who can look at and from who or for whom it's intended to 
benefit.” 33 
“we didn't design it to make everybody have a home.” 33 
“But we shared it as broadly as possible. “ 33 
“That aren't disease-specific in our focus that, and if you look at the projects, they're kind of all 
over the place except for in this Center for Excellence for Osteoporosis.  They're obviously going 
to focus on osteoporosis.  The other projects are really all over the place, and as much method - 
half of them are really methodologic as opposed to disease-focused.  I don't think you look at it 
and say they obviously have a bias against something.” 33 
“And we've made it pretty clear that in the announcements that it's blue sky.  If you've got an 
idea - essentially, that idea for which you - that some of our resources would prove useful if you 
had some money to access them, and I want to get that before we finish here.” 34 
“, I think, even just the process was beneficial to the investigator.  I think of one.  We had a 
researcher in human sexuality proposed something related that was not of interest at all to Merck, 
but he wasn't really aware of Regenstrief or the INPC so just going through the process, I 
introduced him to the data corp, and he met up with a researcher at Merck, and they didn't get 
funded ultimately, but he had said, you know, this is great.  I didn't even know this was here and 
now this is something that I can do.  So, even the people who ended up having these areas that 
were way outside of what Merck was talking about and were interested in, they got something 
useful there.” 34 
“but it essentially divides things into something that's high interest, moderate interest and really 
no interest, low interest, and eventually things that go to low interest, they don't get asked to 
flush out their charters and the hot and moderate ones end up with the proposals.  We go and 
kind of just say same three categories and then among the hot interest say which ones we 
definitely want to do and then Merck has to say how much money they have and then if we get 
all the hot ones, then we have to go down and rank the moderate ones and go down and get 
those.  So - and it's nice that we can end up funding - 30-40 percent of the proposals that are 
initially submitted are ultimately funded.  So it's not a matter of you just taking a real small tip of 
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the iceberg, and so there is an opportunity to go down and there's opportunities where they say, 
this is one you ought to move up a little.  We really want - there's somebody who really wants to 
do this and a couple places, somebody else at Merck said I want to do that one.  I'll put extra 
money into this.  Merck actually shopped these things in their own shop to find extra money for 
them.” 35 
 “One is that there are people who are non-voting members who sit at that decision meeting.  So 
there's three people on each side who vote, but there are some non-voting folks who are present 
and are able to give feedback and share.  For whatever that's worth.” 35 
“The second is that the priorities, we probably read these and evaluate them as more than just - 
you know, we think about the teams, right?  So we'll look and say this person was on - last year, 
this team worked together.  They were an extremely good team, which might be the way the 
investigator is evaluated in NIH section, but we know like these guys work well together or 
don’t, and also priorities shift… and it's sort of the same thing where like there are things that we 
took and then between the RFP cycle and the voting cycle, they have major changes in their 
priorities at Merck, and it affected what was selected and so some people get the short end of the 
stick.  So, I think it can happen in both scenarios.” 36 
“There were a couple of projects where they said, you know, they're not ready for this yet.  
They're still developing this whatever the approach was and so let's let this percolate another year 
and it will almost certainly get funded next year.  So, it's kind of like revise and resubmit….well 
so we know what's coming.  We've got a sense for it, and yet, I don't - I haven't gotten the sense 
from the process - and I'm pretty sensitive to this - that there's bias involved.  I think that there's - 
that certain people who come up with ideas, those ideas resonate and they percolate to the top, 
and that happens in a little bit different way.  I don’t get a sense that Merck is either openly or 
surreptitiously driving the agenda, and I don't think we are either.  …The ones that are in the 
middle, but these people kind of churn and through the thing, it kind of percolates more towards 
the top, and it gets rewarded for doing that, and they do it with help and advice from us at each 
step of the way.” 36 
“In other words, if we've selected things that fit with the declared mission of our partnership, is 
that fair?  If we selected things that fit with our RFP that we sent out four months ago, is that 
fair?  In other words, to whom do we owe this fairness and, you know, how is that defined?” 36 
and erics response 
Protection of Human Subjects 
“Only the IRB refusing - counting so many things as exempt.  We're like we want you to please 
review this, and they won't.  They say it's exempt.” 37 
“We circulate the ICMJE guidelines and say you have to abide by them, but they're pretty broad 
and so…They're not signing.  They're encouraged.” 38 
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“The reason Merck came to us is we're sitting on a mountain of data that's somebody else's data.  
And yeah, we follow all the IRB rules.  We following the INPC rules, etc. … But in the end, we 
don't own the data.  We're getting value from the data that other people are paying to put there, 
and they know that we're using them for research, and I know that the health organizations think 
that we get rich off of our grants, and they don't get anything off of them… years that we could 
be called on, especially when we are making money off of this that's supporting our research 
mission.  Now, we're not individually making money off of it, but it's supporting our research 
mission.  It's part of our organization and we're moving the company forward based on 
somebody else's asset, and Deloit is a good example.  Their first approach to us was send us all 
your data.  Sell us all of your data, and I don't know that there is anything that would have 
prevented us from doing that because there is nothing in the INPC charter that says we can't do 
it.  We'd have to get permission to do research on the data, but it's not to say that we can't upload 
it somewhere because we're already uploading it to us.” 39 
“And I - I'm guessing this issue is gonna show up in other places as other information exchanges 
happen, as other organizations put in health records, and they don't really know how to deal with 
them.  This is gonna bubble up, and I'd like to have a better answer for it than we currently 
have.” 40 
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APPENDIX 5 
SURVEY INSTRUMENT FOR: 
Survey of Regenstrief Investigators and Staff on Experiences, Knowledge, and Perspectives 
of the Regenstrief-Merck Partnership 
PI: Eric M. Meslin, PhD 
Introductory Statement to Participants: Thank you for agreeing to participate in this study. 
When responding to the statements and questions contained in this survey, please remember that 
we are inquiring about your opinions of the Merck-Regenstrief partnership.  
We’d also like to remind you that your participation in this study is completely voluntary, and if 
for any reason you wish to end your participation in this survey, you can stop participating at any 
time. We ask that you take this survey in a private space and on a secure network. If any issues 
or concerns should arise after your participation in this study, you may contact the PI at 
emeslin@iu.edu. This survey should last approximately 10 minutes and we ask that you only 
take the survey once. 
Preliminary Questions 
1. What is your affiliation with Regenstrief Institute? 
a. Research Scientist 
b. Affiliated Scientist 
2. Have you ever been directly supported by the Merck-Regenstrief partnership? 
a. YES 
b. NO 
3. In what capacity or role were you supported by the partnership? 
a. Principal Investigator 
b. Co-Investigator 
c. Other 
i. If “Other,” please specify 
4. In your opinion, how knowledgeable are you of the Merck-Regenstrief partnership? 
(Likert Scale) 
a. Very knowledgeable 
b. Knowledgeable 
c. Somewhat knowledgeable 
d. Not knowledgeable 
Questions for Those Who Selected either (b) or (a) in Question #1: 
(Unless otherwise noted, participants will be asked to respond to the statements from the options 
given in the Likert Scale below.)   
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Likert Scale: Strongly Agree, Agree, neither agree nor disagree, disagree, strongly disagree, I 
don’t know/not applicable 
Stem: The Merck-Regenstrief partnership:  
5. Promotes investigator-initiated science  
6. Permits investigators to continue on-going collaborations with other research collaborators 
or teams.  
7. Ensures that all Regenstrief investigators are given equal opportunity to submit proposals 
for funding in the partnership.  
8.  Effectively disseminates the funding opportunities to all investigators who are eligible to 
apply. 
9. Pressures faculty to work outside of their own research interests.  
10. Results in the exploitation of students and fellows. 
11. Adequately protects investigators’ intellectual property rights. 
12. Has an acceptable data sharing policy. 
13. Has established clear criteria for which projects will be funded. 
14. Chooses research areas of focus in ways that are problematic. 
a. Branch: if participant chooses strongly agree or agree: 
i. Please describe why or in what ways you feel the research areas of focus 
are chosen in problematic ways. Please cite specific examples if able. 
(Text Box) 
15. Chooses research areas of focus that prioritize Merck’s interests. 
16. Chooses research areas of that prioritize Regenstrief’s interests. 
17. Explains the procedures for applying for funding to all eligible investigators. 
18. Is likely to benefit patients  
19. Is likely to benefit society  
20. Is beneficial to Regenstrief 
a. Branch: if agree or strongly agree: 
i. Partnering with Merck has benefited Regenstrief by: 
1. Providing more research funding (Likert Scale) 
2. Creating an environment more supportive to partnering with 
outside entities (Likert scale) 
3. Creating a more effective system for managing projects (Likert 
Scale) 
21. Has been beneficial to me 
a. Branch: if agree or strongly agree 
i. Please describe the ways in which the Merck-Regenstrief partnership has 
benefitted you. (Text Box) 
ii. If disagree or strongly disagree 
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iii. If you believe the Merck-Regenstrief partnership has negatively affected 
you in some way, please describe why you believe this and in what ways it 
has done so. If the partnership has simply not been to your benefit but has 
neither been to your detriment, please leave the text box blank. 
NO STEM 
22. I feel there is a conflict between my professional goals and the goals of the partnership.  
23. I have concerns that some projects conducted in the partnership are unethical. 
24. The partnership has had the following effect on my ability to compete for research funding 
(different likert scale): 
a. Strengthened it. 
b. Neither strengthened nor weakened it. 
c. Weakened it. 
Additional Questions for those who answered “(a) YES” in Question #1 (i.e. only those who 
HAVE been supported by the partnership): 
STEM: The Merck-Regenstrief partnership: 
25. Has effective mechanisms to manage conflicts of interest. 
26. Ensures the right of all investigators to publish 
27. Encourages timely dissemination of research results. 
NO STEM: 
28. There is effective communication between Regenstrief and Merck co-Investigators. 
29. My right to publish research findings from my work in the partnership does not differ 
from my right to publish from my work on other projects. 
30. The projects I’ve been involved in the partnership are undertaken according to the highest 
ethical standard
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PRINCIPLES        BENCHMARKS  
   
Academic Freedom  1. Promote investigator-initiated science and protect the ability of investigators to attract and maintain federal research 
support. 
 
 2. Permit investigators to initiate or continue collaboration with any other qualified group, person, or entity.  
 3. Ensure that all investigators involved in the partnership are given equal opportunity to submit proposals for funding.  
 4. Avoid obligating faculty to work outside their own self-defined scientific area.  
   
Conflict of Interest Policy and 
Management  
5. Protect students, fellows, and post-doctoral fellows involved in collaborative projects from exploitation.  
 6. Ensure that effective mechanisms exist to eliminate, control or manage conflicts of interest in the partnership.  
   
Intellectual Property  7. Ensure all investigators and both partners retain their proprietary and intellectual property rights throughout and after 
the partnership. 
 
   
Data Sharing and Access  8. Ensure that data sharing arrangements are explicit and that all rights to access data are fairly negotiated at the outset 
of the partnership. 
 
   
Effective Governance  9. Establish parameters for what type of projects will and will not be funded (e.g. add-on projects, training, pilot studies).  
 10. Create ways to protect each party from an unexpected end to the partnership.  
 11. Assess formally the efficiency, effectiveness, and achievements of the partnership on an annual basis.  
 12. Ensure that clear, comprehensive, and efficient procedures exist for all governance entities of the partnership and are 
known to all investigators. 
 
   
Protection of Human Subjects   13. Ensure that all investigators, staff and other participants in the partnership have adequate training in the responsible 
conduct of research and related ethical issues. 
 
 14. Ensure that all projects in the partnership aim to satisfy the highest ethical standards.  
   
Publication  15. Ensure the right of all researchers associated with the partnership to publish.  
 16. Disseminate all research results at the conclusion of collaborative studies in a timely fashion.  
 17. Ensure authorship follows ICMJE guidelines.  
   
Social, Scientific, and Industrial Value  18. Maintain competitive advantage in the specified research domains.  
 19. Structure the research to maximize potential benefit for communities and society.  
 20. Structure the partnership to have the best chance of benefiting both partners and harming neither.  
   
Transparency  21. Widely publicize the partnership agreement and collaborative opportunities to the public and employees.  
 22. Establish procedures for frequent and effective communication between partners.  
 23. Ensure both partners are aware of other partnerships each may be involved in.  
   
APPENDIX 6 
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KEY TO REPORT CARD 
GREEN Benchmark MET 
YELLOW JURY’S OUT on Benchmark 
RED Benchmark NOT MET 
WHITE Insufficient evidence 
 Principle MET 
 JURY’S OUT on Principle 
 Principles NOT MET 
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